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Stem cell biology is an exciting field that will lead to significant 
advancements in science and medicine. We hypothesize that inducing the 
expression of stem cell genes, using the embryonic stem cell gene nanog, will 
reprogram cells and dedifferentiate human mesenchymal stem cells into 
pluripotent stem cells capable of neural differentiation. The aims of initial 
studies are as follows:  
Aim 1: Demonstrate that forced expression of the embryonic stem cell 
gene nanog induces changes in human mesenchymal stem cells to an 
embryonic stem cell-like phenotype. 
Aim 2: Demonstrate that induced expression of nanog up-regulates the 
expression of multiple embryonic stem cell markers and expands the 
differentiation potential of the stem cells. 
Aim 3: Demonstrate that these nanog-expressing stem cells have the 
ability to differentiate along neural lineages in vitro and in vivo, while mock-
transfected cells have an extremely limited capacity for transdifferentiation. 
Alternatively, we hypothesize that embryonic stem cell genes can 
become activated in malignant gliomas and differentially regulate the 
subpopulation of cancer stem cells. This study examines the role of 
embryonic stem cell genes in transformed cells, particularly cancer stem cells. 
These studies explore has the following objectives: 
Aim 1: Isolate different sub-populations of cells from tumors and 
characterize cells with stem cell-like properties. 
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Aim 2: Characterize the expression of embryonic stem cell markers in 
the sub-population of cancer stem cells. 
Aim 3: Examine the effects of histone deacetylase inhibitors at 
inhibiting the growth and reducing the expression of stem cell markers.  
Our research has demonstrated the potential of the embryonic 
transcription factor, nanog, at inducing dedifferentiation of human bone 
marrow mesenchymal stem cells and allowing their recommitment to a neural 
lineage. Specifically, we used viral and non-viral vectors to induce expression 
of NANOG, which produced an embryonic stem cell-like morphology in 
transduced cells. We characterized these cells using real-time PCR and 
immunohistochemical staining and find an up-regulation of genes responsible 
for pluripotency and self-renewal. Embryonic stem cell markers including 
Sox2, Oct4 and TERT were up-regulated following delivery of nanog. The role 
of nanog in the expression of these markers was further demonstrated in our 
induced-differentiation method where we transfected embryonic stem cell-like 
cells, that have been transduced with nanog flanked by two loxP sites, with a 
vector containing Cre-recominase. We tested the ability of these nanog-
transfected cells to undergo neural differentiation in vitro using a neural co-
culture system or in vivo following intracranial transplantation.  
Our next study characterized patient-derived glioblastoma cancer stem 
cells. We found that cells isolated from serum-free stem cell cultures were 
enriched for stem cell markers and were more proliferative than the bulk 
population of cells grown in convention serum-supplemented media. These 
cancer stem cells expressed embryonic stem cell markers NANOG and OCT4 
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whereas non-tumor-derived neural stem cells do not. Moreover, the 
expression of stem cell markers was correlated with enhanced proliferation 
and could serve as a measure of drug effectiveness. We tested two different 
histone deacetylase inhibitors, trichostatin A and valproic acid, and found that 
both inhibited proliferation and significantly reduced expression of stem cell 
markers in our cancer stem cell lines. These data demonstrate the potential 
use of stem cell genes as therapeutic markers and supports the hypothesis 
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NANOG OVEREXPRESSION ALLOWS HUMAN MESENCHYMAL STEM 
CELLS TO DIFFERENTIATE INTO NEURAL CELLS 
Chapter Summary 
Stem cell therapies have been proposed as a treatment option for 
degenerative disease, like Alzheimer’s disease (AD), but the best stem cell 
source and their therapeutic efficacy remain uncertain. Embryonic stem cells 
(ESCs) can efficiently generate multiple cell types, but pose ethical and 
clinical challenges, while the more accessible adult stem cells have a limited 
developmental potential. The primary objective of this article is to show that 
following over-expression of an ESC gene, nanog, adult human mesenchymal 
stem cells (HMSCs) could be dedifferentiated into cells exhibiting ESC 
characteristics based on morphology, immunohistochemical staining, and 
gene expression. After expansion, nanog-transfected HMSCs had the 
potential to be directed toward neural cell lineage under influence of 
conditional media from differentiated human neural stem cells using a 
membrane-separated co-culture system. Recommitted cells differentiated into 
cells immunopositive for βIII-tubulin and glial fibrillary acidic protein, indicating 
the presence of neurons and astrocytes, respectively. We further 
demonstrated the ability of dedifferentiated HMSCs to survive, migrate, and 
undergo neural differentiation in vivo in rodents. This data offers an exciting 





Dementia is a serious medical illness that affects an estimated 24.3 
million people worldwide[1] at a cost of $315.4 billion annually[2]. Severe 
cognitive impairment from Alzheimer’s disease (AD) is associated with the 
majority of dementia cases. While most pharmacological treatments for AD 
fail to improve cognition, several lines of evidence suggest that neuro-
replacement therapy may reverse cognitive impairment. Namely, 
neurogenesis is associated with cognition and is congruously impaired with 
aging.[3, 4] Second, neural stem/progenitor cell proliferation and 
differentiation are significantly diminished in AD and Down’s syndrome 
models both in vitro and in vivo.[5-8] Finally, cognitive performance improves 
through increasing neurogenesis from an enriched environment[9-11], 
pharmacological treatment[11, 12], or following stem cell transplantation[12-
16]. Although Gallagher’s group failed to show a relationship between 
neurogenesis and cognition in a normal aging rodent model,[17, 18] the 
collective body of evidence suggests that neurogenesis is important for 
maintenance of normal brain function. 
Embryonic stem cells (ESCs) have been proposed as treatment for 
neurodegenerative diseases because of their pluripotency, but concerns over 
ethics[19-21], immune response[22-24] and tumor formation[25-28] have 
been major barriers for their clinical use. Utilization of adult stem cells could 
eliminate these issues because they can be harvested from a patient and 
autologously transplanted back to the patient. However, the ability of adult 
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stem cells, such as human bone marrow-derived mesenchymal stem cells 
(HMSCs), to develop along multiple lineages is limited. Although studies have 
claimed that HMSCs transdifferentiate into cells outside their restricted germ 
layer, the transdifferentiation could have been from a very limited population 
of HMSCs[29-31] or due to the low frequencies of cell fusion, which allow 
MSCs to acquire characteristics of multiple cell types by fusing to somatic 
cells.[32-34] Therefore, a strategy to increase the potency of adult stem cells 
is requisite for their use in neurotherapy.  
In a prior study, we demonstrated that HMSCs treated with 
bromodeoxyuridine (BrdU) undergo neural differentiation following 
transplantation in the brains of rats and improve cognitive function.[13] 
However, efficiency of transdifferentiation and concerns with the use of BrdU, 
which is incorporated into the DNA as a thymidine analog, led us to explore 
other strategies. 
One possible strategy is cell fusion that would alter the characteristics 
of the adult stem cells based on the exogenous cell used for merging. This 
method could change the potency of cells allowing them to develop into cells 
beyond their respective lineage.[35-38] The fusion of somatic cells to ESCs 
prompts expression of the embryonic stem cell gene Oct-4.[38, 39] Thus, the 
expression of stem cell genes that regulate self-renewal and pluripotency may 
play an integral role in reprogramming the cell lineage.  
Earlier studies have indicated that the expressions of critical stem cell 
genes are capable of maintaining ESCs in a pluripotent state. The 
suppression of ESC differentiation has been demonstrated with the over-
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expression of ESC genes including nanog[40, 41], Pem[42] and Rex1[43], 
although the presence of elevated levels of Oct-4 was insufficient to guard 
against ESC differentiation.[44] In this study, we tested our hypothesis that 
developmental potency of MSCs can be gained by changing the gene 
expression profile through the over expression of nanog, and the resulting 
cells can be transdifferentiated into neural cells. This technology may allow us 
to use patients’ own HMSCs to treat neurodegenerative diseases, such as 
AD. 
Materials and Methods 
Cell Culture 
Adult human bone marrow-derived HMSCs (Cambrex) were cultured in 
DMEM (Invitrogen) supplemented with 1% antibiotics (Invitrogen) and 10% 
FBS for improved HMSC growth (StemCell Technologies). Per Cambrex 
product information, mesenchymal stem cells are harvested and cultured from 
normal human bone marrow. Cell purity is far higher than cells from traditional 
Dexter cultures. Cells are tested for purity by flow cytometry and for their 
ability to differentiate into osteogenic, chondrogenic and adipogenic lineages. 
Cells are positive for CD105, CD166, CD29, and CD44. Cells test negative for 
CD14, CD34 and CD45. Media systems are available to support growth of 
HMSCs, and their differentiation into adipogenic, chondrogenic, and 
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osteogenic lineages. Cells were cultured in T75 tissue culture treated flasks 
(BD Biosciences) and incubated in a CO2 chamber at 37℃ with 5% CO2 
(NuAire). Co-culture experiments were carried out using differentiated NSCs 
in Falcon tissue culture treated 6-well plates (BD Biosciences). Prior to co-
culture, fetal-derived human NSCs (Cambrex) were expanded in serum-free 
NSC medium of DMEM/F12 (Invitrogen) supplemented with B27 (1:50, 
Invitrogen), basic Fibroblast Growth Factor (bFGF, 20 ng/ml, R&D Systems), 
Epidermal Growth Factor (EGF, 20 ng/ml, R&D Systems), heparin (0.18 U/ml, 
Sigma), and 1% antibiotics (Invitrogen). Cells were allowed to spontaneously 
differentiate for one week in tissue culture treated 6-well plates containing 
serum-free neural basal medium. 
For co-culture, cell culture inserts with a semi-permeable membrane 
with 0.4 μm pores (BD Biosciences) were used to separate the Nanog-
transfected HMSCs from the differentiated HNSCs. This allowed for the 
dynamic exchange of secreted factors and eliminated direct cell contact to 
avoid possible cell fusion. Nanog- or mock-transfected HMSCs were then 
transferred to co-culture to promote neural differentiation. To eliminate Nanog 
expression in viral-loxP-Nanog-transduced HMSCs prior to the co-culture, 
plasmids containing the Cre recombinase gene regulated by an EF1α 
promoter (Addgene, plasmid 11918) were transfected into the cells using the 
FuGene 6 reagent. Cells were allowed to differentiate for 10 days and then 
stained for early (βIII-tubulin) and mature (MAP2) neuronal markers and 
astrocytic markers, GFAP and S100. 
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Cloning of Nanog Gene 
Nanog was originally cloned from male genomic DNA that was pre-
digested with the restriction enzymes NotI, XbaI, and SpeI, then amplified by 
PCR using Nanog-specific primers, (CGTTCTGCTG- GACTGAGCTGGTT, 
CGGGCGGATCACAAGGTCAG). PCR conditions consisted of pre incubation 
at 94℃ for three minutes, 30 cycles consisting of 94℃ for one minute, 52℃ for 
30 seconds, and 72℃ for three minutes, and post dwells at 72℃ for 10 
minutes. The PCR pro- duct was then placed into a mammalian expression 
vector (TopoHisMax 4.1, Invitrogen) according to manufacturer’s protocol. 
The cloned sequence was confirmed by DNA sequencing. 
Production of Lentivirus Containing Nanog 
The gene encoding for Nanog (gift from Austin Smith, MD University of 
Cambridge) was amplified using the Herculase II fusion DNA polymerase 
(Promega) and gene-specific primers containing a BamHI enzyme-cutting site 
in the forward primer and a SalI-cutting site in the reverse primer 
(ATAGGGATCCACATGAGTGTTGACCCAGCTT, 
ATAGGTCGACTCACACGTCTTCAGGTTGCA). The PCR amplified Nanog 
was sub-cloned into the pLox lentiviral vector (gift from Didier Trono, MD and 




Production of a lentiviral vector containing the Nanog sequence was 
carried out using a vector containing a LoxP site. The pLoxNanog vector, the 
packaging vector pCMVΔR8.91 (AddGene) encoding for regulatory proteins 
Tat and Rev as well as the Gag and Pol precursors, and a vector for the 
envelope protein VSV-G (Clontech) were used for viral production. The 
aforementioned vectors and lentiviral vectors pLoxNanog and pLoxGFP, 
combined with the packaging and envelope plasmids at a ratio of 2:1:1 
(pLox:pCMVΔR8.91:pVSV-G) [45, 46], were transiently transfected into the 
HEK293T/17 cell line (ATCC) using Lipofectamine (Invitrogen) at a DNA 
(20µg) to Lipofectamine ratio of 1:2.5. The cell culture media was removed at 
24 hours and collected every 12 hours thereafter for the next two days to 
harvest the viral supernatant. 
Non-viral and Viral Gene Delivery 
For non-viral gene transfection, 75% confluent HMSCs were 
transfected with 3μg of Nanog vector using two different reagents, 
Neuroporter (Gene therapy systems) or FuGene 6 (Roche), at DNA to reagent 
ratios of 1:15 and 1:3, respectively. Proliferative clusters began to emerge 
after one week and grew large enough for expansion typically by three weeks. 
Clustered cells that resembled Nanog-transfected HMSCs were passed by 
mechanical dissociation from the feeder layer and subsequently plated with a 
feeder cell layer of HMSCs.  
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For lentivirus-mediated transfection, viral supernatant was transferred 
to HMSC cultures for viral transduction. Delivery of Nanog was analyzed 
through fluorescent microscopy for positive green fluorescent protein (GFP) 
expression. Differentiation was induced through the deletion of the Nanog-
containing proviral sequence with a vector encoding for Cre recombinase 
(Addgene pBS513)[47-49]. The Cre vector, which contains an EF1α promoter, 
was delivered to the cells through chemical transfection. Following Cre-
transfection, cells were used for neural differentiation or gene expression 
analysis at 72 hours post-transfection. All recombinant DNA research was 
performed in accordance with NIH guidelines.  
Gene Expression Analysis 
RNA extraction was performed using TRIzol (Invitrogen) according to 
manufacturer’s instructions. Media was removed from cultured cells and 
incubated with 1ml of TRIzol for five minutes at room temperature. The TRIzol 
solution was phase-separated by an addition of chloroform, thoroughly mixed, 
and centrifuged at 11,500g for 15 minutes. The RNA was precipitated from 
the top aqueous phase by isopropanol, centrifuged at 11,500g for 10 minutes, 
and the RNA pellet was washed with 75% ethanol. The RNA-ethanol solution 
was centrifuged for five minutes at 7,400g, the supernatant removed, and the 
pellet was re-suspended in molecular biology grade water. RNA concentration 
were measured based on absorption and converted to cDNA for PCR 
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analysis. Reverse transcription was performed using an iScript cDNA 
synthesis kit (Bio-Rad). 
Primers used for RT-PCR were GAPDH 
(AGCCACATCGCTCAGACACC, GTACTCAGCGGCCAGCATCG), β-actin 
(TCCTGAGCGCAAGTACTCC, AAGCATTTGCGGTGGACGA), Nanog 
(ACAACTGGCCGAAGAATAGC, AGTGTTCCAGGAGTGGTTGC), Oct-4 
(CTTGCTGCAGAAGTGGGTGGAGGAA, CTGCAGTGTGGGTTTCGGGCA), 
TERF1 (GCAACAGCGCAGAGGCTATTATT, 
AGGGCTGATTCCAAGGGTGTAA), Sox-2 (ATGCACCGCTACGACGTGA, 
CTTTTGCACCCCTCCCATTT), ZFP342 (GAAGGCATCACCCAAAAAGA, 
GCGGTTGAGCTTACTGCTCT), TERT (CGGAAGAGTGTCTGGAGCAA, 
GGATGAAGCGGAGTCTGGA), and eGFP (CCTGAAGTTCATCTGCACCA, 
GGTCTTGTAGTTGCCGTCGT).  
Real-time two-step RT-PCR was performed using a SYBR green PCR 
mix (Bio Rad), carried out in a My-IQ iCycler (Bio Rad) and then analyzed by 
the ΔCt method as previously described [50, 51].  
Stem Cell Transplantation 
Two different transplantation studies were performed with C57/Black 
mice at four months of age in accordance with approved protocols from the 
University of Central Florida’s Institutional Animal Care and Use Committee.  
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The animals were fixed in a stereotaxic apparatus and approximately 
1x10^5 cells in 10μl of phosphate-buffered saline (PBS) were slowly injected 
into the right lateral ventricle (coordinates: AP -1.4, ML 1.8, DV 3.8). 
Experiments were carried out independently using HMSCs dedifferentiated 
through non-viral transfection or lentiviral transduction.  
Stem Cell Transplantation 
Two different transplantation studies were performed with either six 
eight-month Fisher 344 rats for non-viral dedifferentiated cells or C57/Black 
mice for virally-transduced cells for transplantation in accordance with 
approved protocols from the University of Central Florida’s Institutional Animal 
Care and Use Committee. Prior to transplantation, animals were anesthetized 
with intraperitoneal injections of a solution mixture of ketamine hydrochloride 
and xylazine (X-Ject) (1:1 ratio). Adequate sedation was determined by a lack 
of palpebral and tail-pinch reflexes. 
Once properly sedated, animals were set atop a platform of appropriate 
height and secured within a stereotaxic apparatus using the nose clamp and 
ear bars. The heads of the animals were shaved and an anterior to posterior 
incision was made with a surgical scalpel to reveal the skull. Using bregma as 
a reference, the location of the right lateral ventricle was located using a brain 
atlas, and a needle hole was carefully drilled through the skull but not into the 
brain. Approximately 1x10^5 cells in 10µl of phosphate-buffered saline (PBS) 
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were slowly injected into the right lateral ventricle (coordinates: AP -1.4, ML 
1.8, DV 3.8). Cells in solution were kept on ice and adequately re-suspended 
to avoid cell aggregation. Experiments were carried out independently using 
HMSCs dedifferentiated through non-viral transfection or lentiviral 
transduction. Following injection, residual blood was gently cleaned with 
sterile cotton swabs and the incision closed using surgical clamps. Animals 
were post-surgically monitored for signs of bleeding, infection, and behavioral 
changes.   
Brain Sample Preparation 
Animals were deeply anesthetized and perfused using a 10% sucrose 
solution followed by fixation with a 4% paraformaldehyde PBS (pH 7.2). 
Following fixation, brains were removed and placed inside a 20% sucrose/4% 
paraformaldehyde solution and left overnight at 4℃. When the brain settled to 
the bottom of the container, it was froze in isopentane pre-cooled by 
submerging the beaker into liquid nitrogen. The brains were mounted using a 
cryomedium, sliced into 20µm sections using a cryostat at –20℃ and 
collected in PBS and stored at 4℃ until antibody staining. 
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Immunocytochemistry and Immunohistochemistry 
Cultured cells were washed with PBS then fixed with a 4% buffered 
paraformaldehyde (Sigma) solution overnight at 4℃. Following fixation, cells 
were washed with PBS (Sigma) then permeabilized with PBS-Tween (Sigma) 
containing 0.1% Triton-X (Fisher Scientific) for one hour at room temperature. 
Brain sections were washed with PBS then permeabilized by incubation in 
PBS-Tween with 0.1% Triton-X at room temperature for one hour. The 
samples were then incubated for one hour at room temperature in a blocking 
solution of PBS-Tween with 3% donkey se-rum (Jackson ImmunoResearch). 
Primary antibodies TRA-1-60 (MAB4360), SSEA-3 (mab4303), Sox-2 
(AB5603), MAP2 (AB5622), and Oct-4 (mab4305) all from Chemicon, Nanog 
(AF1997, R&D Systems), βIII-tubulin (T8660, Sigma), S100 (S2644, Sigma), 
and GFAP (G9269, Sigma) were added to blocking solution and incubated 
overnight at 4℃. The next day, samples were washed with PBS and 
incubated in the dark with FITC- or TRITC-conjugated secondary antibodies 
at room temperature. Samples were washed with PBS, cover-slipped with 
water-based mounting solution containing DAPI (Vector Laboratories), and 




Cloning of nanog: Sequence analysis showed over 99% sequence 
identity with nanog but did not contain introns, suggesting that it may be 
nanog pseudogene 8 (NANOGP8),[52] one of twelve nanog variants.[52-56] 
The high homology and intact coding region suggests that the cloned 
sequence should be indistinguishable from nanog and the translated product 
virtually identical to the actual nanog protein, with the exception of 
substitutions occurring in residues 16 and 253, changing alanine and 
glutamine for glutamate and histidine, respectively. The cloned gene 
sequence can be segmented into seven distinct regions: the 5’ untranslated 
region (UTR), N-terminal domain, homeodomain, C1 domain, Cw domain, C2 
domain, and the 3’ UTR. The 5’ region contains binding sites for embryonic 
stem cell genes Oct-4 and Sox-2, which are part of a transcriptional regulatory 
loop.[57-60] The 5’ region also contains a p53-binding site within the nanog 
promoter region that facilitates ESC differentiation[61] and is possibly 
responsible for the shift in replication timing observed with neural 
differentiation.[62] The N-terminal region of nanog has transcriptional 
activity[63] and encodes for a sequence containing a SMAD-binding 
domain.[54, 64] The homeodomain portion is similar to the NK-2 and ANTP 
family of homeodomain transcription factors, but comparing 120 different 
homeodomain proteins using BLOcks SUbstitution Matrix (BLOSUM) and 
Point Accepted Mutation (PAM) matrices suggests that nanog represents a 
distinct protein family divergent from both the NK-2 and distal-less gene family 
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(data not shown). The C-terminal domain contains no apparent transactivation 
motifs, but has greater transactivation activity compared to the N-terminal and 
homeodomain.[63, 65] 
The C-terminal domain can be subdivided into three regions: the 
portion immediately following the homeodomain region (C1), the subregion 
containing a unique repeated motif of tryptophan flanked with four polar-
uncharged amino acids (Cw), and a more distal sequence (C2). Cloning of 
nanog inside the pLox lentiviral vector was successful and DNA sequencing 
confirmed a match for the actual nanog gene. The nanog sequence was 
properly inserted into the vector containing LoxP sequence within the long 
tandem repeat, allowing for efficient proviral deletion following delivery of Cre 
recombinase.[55, 56] 
Transfection of nanog: In the current study, human bone marrow 
HMSCs were cultured and grown to 75% confluence and treated with a 
plasmid containing nanog or served as mock-transfected control. Following 
optimization, we achieved transfection rates of less than 5% using non-viral 
transfection. Nanog transfection altered the morphology of cells, producing 





Figure 1: (a) HMSCs over-expressing Nanog displayed ESC-like (v-viii) or EB-
like morphology (ix-xii). Morphological changes seen at three weeks (i,v,ix), 
two (ii,vi,x), three (iii,vii,xi), and six months (iv,viii,xii) post-transfection. (b) 
HMSCs nine days post-transduction with Nanog lenti-virus (ii). Three weeks 
following non-viral Nanog transfection (iii) and three days later (iv). Untreated 
HMSCs showed as a control (i). 
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Two basic cell types were observed; namely, the proliferative clusters 
tended to form either an adherent mass of cells that were ESC-like or more 
spherical, non-adherent/loosely adherent clumps somewhat resembling 
embryoid bodies (EB-like). The EB-like cells originated as small, scattered 
clumps, but formed larger aggregates within weeks. These larger clusters 
were mainly the result of clump aggregation rather than cell proliferation.  
Transfection with the neuroporter reagent appeared to have more 
toxicity and was more likely to produce EB-like cells, therefore FuGene 6 was 
the preferred transfection reagent. Cells that displayed the flattened, ESC-like 
morphology were detected as early as one week, but were usually distinct at 
two to three weeks. The number of colonies produced did not appear to 
directly correspond to transfection rates. Following one week, one or two 
colonies could be observed in the wells. No colonies were able to expand 
without a feeder layer, and only a few colonies were able to expand into larger 
colonies of thousands of cells for subsequent passaging.  
Moreover, the colonies that did form and display ESC-like morphology 
were only found within the nanog-transfected cell cultures. Both of the 
previously defined cell types either adhered and differentiated or underwent 
cell death when transferred to separate culturing flasks with no feeder layer 
(data not shown). The inability of isolated colonies to continually proliferate on 
their own indicates that the majority of non-transfected HMSCs served as a 
feeder layer, helping provide growth factors and aid in cell survival. ESC-like 
colonies were less homologous and displayed greater propensity for 
differentiation than has been reported with ESCs (Figure 1A).  
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There was little difference between ESC-like cells and ESCs for up to 
two months in culture, and while they were able to proliferate, they did not 
appear to grow past 1000µm. However, by three months, gradual changes 
became evident as heterogeneity within the structures became more 
apparent. It is uncertain whether this phenomenon is the result of cells 
undergoing differentiation, reaching a proliferative limit, or the result of 
changes in the underlying feeder layer of un-transfected HMSCs. Control 
HMSCs showed changes in morphology at three months in culture, and by 
three months displayed little or no proliferation. 
Beyond three months, the number of nanog-transfected ESC-like cells 
diminished, and mock-transfected HMSCs showed age-related alterations. 
HMSCs could be cultured for longer periods of time through continuous 
passages, but late-passaged HMSCs displayed changes in morphology, 
including increased cell size, larger cytoplasm, and no detectable proliferation. 
Following one year of culturing and expansion, HMSCs failed to survive and 
few ESC-like cells remained.  
Cells co-transduced with nanog and GFP lentiviruses showed 
prominent cluster formation (Figure 1B). Colonies formed by transduction with 
nanog were easier to maintain and grew much larger than HMSCs chemically 
transfected with nanog. Colonies produced through chemical transfection 
were difficult to maintain as the colonies tended to disperse (Figure 1B).  
Gene expression and immnohistochemistry of nanog-transfected 
HMSCs: Exploring biochemical changes following nanog transfection, we 
performed RT-PCR for nanog and Oct-4 to compare with mock-transfected 
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HMSCs, as well as immunostaining for known embryonic stem cell markers. 
Expression levels of nanog and Oct-4 were absent or low in two different 




Figure 2: (a) RT-PCR shows little or no expression of Nanog and Oct-4 in 
mock-transfected HMSCs but up-regulation of both at two, five, and eleven 
months following Nanog transfection up to 11 month in a culture. GAPDH was 
a control. (b) qRT-PCR of Nanog lentiviral-transduced cells. Up-regulation of 
multiple ESC genes after Nanog transfection (grey) were observed and these 
genes were down-regulated after (black) delivery of Cre recombinase vectors 
to remove Nanog expression. 
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This illustrates the heterogeneity of HMSCs in culture and is consistent 
with the data showing a subpopulation of pluripotent HMSCs.[29-31, 66, 67] 
Following nanog transfection, expression of both nanog and Oct-4 were highly 
elevated at two, five, and eleven months. It was unexpected that either nanog 
or Oct-4 would be expressed following long-term expansion since the few 
remaining cell clusters did not appear to proliferate at one year. Interestingly, 
levels of Oct-4 did not directly correlate with expression of nanog, which is 
consistent with findings that Oct-4 is not directly controlled by nanog.[57, 58, 
68]  
Quantitative gene expression analysis was difficult given the 
heterogeneous population and relatively low frequency of nanog-transfected 
cells. We therefore attempted to select out nanog-dedifferentiated cells using 
a lentiviral system and green fluorescent protein. Using lentiviruses to deliver 
nanog and GFP, we created dedifferentiated cells that were more 
homogenous, highly proliferative, and easily expandable. In fact, the cells 
were able to grow with or without feeder cells for over 40 passages.  
Quantitative real-time PCR was performed on lentiviral-transduced 
cells and showed a dramatic increase in most of the ESC genes tested. We 
were able to detect low levels of both nanog and Oct-4 in two of three HMSC 
batches tested, but telomerase expression was absent. Following forced 
expression of nanog, we measured dramatic increases in nanog, Sox-2, zinc-
finger protein 342, TERF1 and telomerase. Given the lack of telomerase 
expression, we assigned the lowest value for detection in order to perform an 
analysis that does not allow for “zero” expression. We observed only a 
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modest, yet statistically significant, increase in levels of Oct-4 to four times the 
normal level (Figure 2). The measured changes, particularly the sudden 
expression of telomerase and increase in TERF1, demonstrate fundamental 
changes in the HMSCs following delivery of nanog. Previous work has 
revealed that human HMSCs fail to express telomerase and have a unique 
telomerase biology compared to other stem cells,[69, 70] so the link between 
nanog and telomerase is an exciting area that warrants exploration.  
Removing nanog and GFP using a vector encoding for the Cre 
recombinase enzyme should reverse gene expression changes in the viral-
transduced cells. Recombination and gene excision was successful, as most 
viral-transduced cells were negative for GFP post-Cre transfection, allowing 
for neural differentiation. Additionally, real-time PCR reveals an 89% decrease 
in GFP expression in viral-transduced cells 72 hours following delivery of Cre 
(data not shown). We compared changes in gene expression changes in Cre-
transfected, virally-dedifferentiated cells and found reduction in most stem 
cells genes. Nanog, Oct4 and TERF1 showed a 70% to 80% decrease in 
expression, while Sox-2 and telomerase showed decreases of approximately 
98% each (Figure 2b). 
Immunohistochemical staining was performed using antibodies against 
the ESC markers nanog, Oct-4, stage-specific embryonic antigen-3 (SSEA3), 
and keratan sulphate-associated antigen TRA1-60. If nanog dedifferentiates 
HMSCs, transfected cells should stain positive for ESC markers. The vast 
majority of untreated cells failed to stain for any ESC markers, but a small 
population (approximately 1%) of cells, did show positive staining for 
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transcription factors Oct-4 and nanog, while faint staining for surface markers 
was seen in about 5% of cells (Figure 3). Alternatively, nanog-transfected 
cells did display positive staining for the ESC transcription factors nanog and 
Oct-4 within the proliferative cell clusters, although not in the surrounding 
feeder layer of HMSCs. Nanog-transfected cell clusters also showed positive 
expression of ESC surface markers SSEA3 and TRA1-60 (Figure 3). 
 
  
Figure 3: Immunocytochemistry of Nanog transfected HMSC colonies showed 
strong immunoreaction for ES cell markers after15 weeks in a culture (v-viii) 
while there is no expres- sion of ES cell markers in mock-transfected HMSCs 
(i-iv). The cells were immunostained for Nanog (i, v), Oct-4 (ii, vi), SSEA-3 (iii, 
vii), and TRA-1-60 (iv, vii). 
This staining pattern was more apparent with the use of the GFP and 
nanog lentiviral-transduced cells. Following transduction with nanog and GFP, 
large ESC-like colonies began to form. GFP expression appeared localized to 
ESC-like colonies and showed positive staining for manog and Sox-2, unlike 
non-treated HMSCs (Figure 3B). Taken together, it appears that forced 
expression of nanog results in the dedifferentiation of HMSCs and induces the 
expression of ESC markers. 
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We next tested the ability of nanog-transfected cells to undergo neural 
differentiation using a previously established co-culture system. 
Dedifferentiated cells were placed in co-culture consisting of a feeder cell 
layer separated by a semi-permeable membrane to eliminate direct cell 
contact. The feeder cells used were neurons and glial cells derived from 
human neural stem cells, and were grown as neural spheres and cultured in 
serum-free basal media. This system allows for the exchange of growth 
factors and eliminates the concern over cell fusion since it prevented direct 
cell contact between the HMSCs and underlying feeder cells. Cell clusters 
adhered to the membrane surface and differentiation occurred as cells 
radiated outwards. Control HMSCs adhered to the membrane surface but 
failed to differentiate into neurons and astrocytes. The differentiation pattern 
was tested by immunostaining against βIII-tubulin and GFAP, neuronal and 





Figure 4: With mock-transfected HMSCs showed no ESC- like colony 
formation (i,v) nor GFP expressions (ii,vi) and immunoreactivities for Nanog 
(iii) and Sox-2 (vii) are not detected. Lentiviral transduction with Nanog and 
GFP in- duced colony formation (ix, xiii) and GFP expression (x, xiv), and 
positive for Nanog (xi) and Sox-2 (xv) immunore- activities. DAPI is used 
counter stain of nuclei (iv, viii, xii, xvi). 
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The un-transfected HMSCs did not show positive staining for the 
neuronal marker βIII-tubulin, but approximately two percent of the cells did 
show weak expression of GFAP. This may represent a subpopulation of 
pluripotent HMSCs[30, 66] that is capable of differentiating into astrocytes. 
Modified cells formed spherical clusters with a similar appearance to 
differentiated neural stem cells, forming a web-like network of neurons and 
astrocytes that stained positive for both βIII-tubulin and GFAP (Figure 5). 
However, βIII-tubulin and GFAP are early lineage commitment markers, so we 
examined the expression of MAP2 and S100 to determine if these mature 
neuronal and astrocytic markers would be expressed following neural 
differentiation to our dedifferentiated cells. Induction of differentiation in the 
viral-transduced cells was achieved by first transfecting the cells with a vector 
encoding for Cre recombinase, then placing the cells in conditioned media for 
neural differentiation. Cre-transfection was successful, as evident by the 
majority of cells now being GFP negative. We found that some cells did show 
positive staining for both markers, and most cells were negative for GFP 




Figure 5: After co-culture with differentiated human neural stem cells, naive 
HMSCs showed few GFAP (red) but no βIII-tubulin (green) immunoreactivites 
(i). While Nanog- transfected HMSCs forming clusters of cells co-cultured with 
differentiated human neural stem cells attached to the culture insert 
membrane and migrated outward. They were positive for GFAP (red) and βIII-
tubulin (green) immunoreactivites indicating neural differentiation of the cells, 
(low magnification in ii, high magnification in iii). Differentiated Nanog-
transfected HMSCs are also stained positive for MAP2 (green) and S100 (red) 






Figure 6: After transplantation into mice, Nanog-GFP transfected HMSCs 
HMSCs are capable of migration into hippocampus dentate gyrus (i). 
Immunostaining specific to human βIII-tubulin (green) and GFAP (red) 
indicated that the transplanted Nanog-transfected HMSCs after Cre 
recombinase treatment differentiated into neurons and astrocytes in the 
dentate gyrus (ii, iii) and CA1 regions (iv) of the hippocampus, respectively. 
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Immunohistochemical staining shows expression of early neuronal 
(βIII-tubulin) and astrocytic (GFAP) markers at three days in neural 
differentiation culture. Cells were cultured for two weeks and stained for 
mature neural markers. Cells stained positive for MAP2 and S100, indicating 
the cells were able to express mature neuronal and astrocytic makers, 
respectively.  
Transplantation results: We tested the cell fate and migration of non-
viral and lentiviral dedifferentiated HMSCs in vivo three weeks post-
transplantation. Following sacrifice, the brains were sectioned and examined. 
None of the animals displayed evidence of tumors, but a separate cluster of 
cells was observed in one region of brain sectioning, presumed to be from the 
original transplantation. Immunohistochemical staining for human βIII-tubulin 
and GFAP did reveal evidence of both in vivo neuronal and glial 
differentiation. Moreover, the presence of transplanted cells, marked by the 
expression of human neural markers or GFP in the Cornu Ammonis fields of 
the hippocampus proper and dentate gyrus regions, is encouraging given the 
role of these structures in learning and memory (Figure 6). 
The high frequency of transdifferentiation demonstrates a new 
technology that neither relies on cell fusion nor the enrichment of low 





This study demonstrates a novel method of dedifferentiating adult stem 
cells by over-expressing genes regulating pluripotency, with the end goal of 
facilitating neural transdifferentiation of HMSCs, which may allow us to 
perform autologous cell therapies for individuals with AD and other 
neurodegenerative diseases. Nanog transfection of HMSCs produced 
proliferative cells with morphological and gene expression similarities to 
ESCs.  
We previously demonstrated that treatment with the nucleotide 
derivative BrdU allows for transdifferentiation,[13] and other groups have 
demonstrated that fusion of stem cells and somatic cells can alter cell 
properties.[34, 37, 38, 71] In the current study, we show that HMSCs can be 
dedifferentiated by gene delivery of only nanog, although other factors already 
present in the cells may contribute to forming ESC-like cells. Recently, 
delivery of four factors induced pluripotency in mouse fibroblasts. Their use of 
transcription factors Oct-4, Sox-2, and KLF4 along with the oncogene cMyc 
was sufficient to induce pluripotent transformation.[72-75] These results have 
been independently achieved by different labs using human cells with the 
same set of genes[76-78] or with a combination of nanog, Oct-4, Sox-2, and 
Lin28.[79]  
We found levels of Oct-4, Sox-2 and other genes related to 
pluripotency and self-renewal were significantly increased after nanog over-
expression. Previous reports failed to show formation of ESC-like cells using 
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any single ESC gene when delivered to stem cells or fibroblasts,[80, 81] nor 
by combining Oct-4, Sox-2, Klf4 and Myc in adult HMSCs.[77] The use of 
additional vectors encoding for the simian virus large T antigen (SV40T) and 
the catalytic subunit for telomerase (hTERT) were able to produce a few 
colonies but still showed cellular loss with expansion.[77] 
The difficulty in converting HMSCs is likely the result of a number of 
critical factors. First, mesenchymal stem cells have a limited capacity for 
expansion and vary in their ability to proliferate and differentiate, qualities that 
decrease with age and vary among sources. They are sensitive to culturing 
conditions, particularly plating density, supplements and serum quality.[82-85] 
Gene delivery experiments are also challenging in these cell types given their 
difficulty to transfect, death from toxicity,[86-89] their propensity to undergo 
senescence after several passages,[69, 90, 91] or toxicity associated with 
viral transductions.[89, 92] Additionally, heterogenetity within HMSCs and 
variation between cultures may account for conflicting results. Research with 
HMSCs has often produced conflicting results, especially when examining 
proliferation and stem cell markers.                    
Previous studies are inconsistent regarding the expression of 
embryonic stem cell transcription factors Nanog, Oct-4, and Sox-2 in adult 
stem cells. Oct-4 is present at low levels in HMSC in vitro cultures or can be 
induced in a subtype of cells using various culture conditions.[30, 84, 93, 94] 
However, low levels sox2 and nanog are detected in some, but not all 
HMSCs.[67, 84, 95-97] This inconsistency extends to telomerase activity and 
the ability to immortalize HMSCs. 
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Similar to genes associated with pluripotency, telomerase activity has 
been detected in MSCs by some groups,[98, 99] but not by others.[69, 70, 
100-102] Conflicting results are also observed when groups have attempted 
to immortalize HMSCs through viral delivery of telomerase. Overexpression of 
telomerase appears to overcome early senescence and generate 
immortalized cell lines[103-106] while other groups report hTERT alone is 
insufficient.[100, 101] Alternatively, only a subpopulation of HMSCs may be 
dedifferentiated by nanog. Presumably cells that endogenously express other 
necessary stem cell genes would undergo dedifferentiation. This hypothesis is 
supported by the ability to convert neural stem cells, which already express 
many stem cell factors including Sox2 and cMyc, to pluripotent cells through 
forced expression of two factors, Oct-4 and Klf-4,[107] or just Oct-4 
alone.[108-110]  
In addition to the presence of critical stem cell genes, the level of 
expression is likely to be imperative in determining cell conversion. Since the 
combination of Oct-4 and Sox-2, which up-regulates nanog, failed to convert 
the adult cells to ESC-like cells,[59, 60] high levels of nanog may be the 
critical factor. Other research found that selection of the cells expressing high 
levels of nanog after transfection with combination of Oct-4 and Sox-2 has 
yielded ESC-like colonies.[74] 
We observed that the number of ESC-like cell colonies that formed 
after nanog transfection did not directly correspond to the number of cells 
receiving the gene. This may be due to the heterogenous population of 
HMSCs, which varyingly express other factors required to produce ESC-like 
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cells. Passage number of HMSCs may contribute to variability in results, 
because changes to HMSCs’ ability to differentiate and rate of proliferation 
are evident by passage six.[90] Continuous passage of cells produces 
alterations and cell senescence, the proliferative limit of which is commonly 
referred to as Hayflick’s limit.[90, 91]  
Cells receiving a non-viral transfection of nanog tended to lose 
proliferative capability while lentiviral-transfected nanog cells can be 
maintained over forty passages. HMSCs show extremely low rates of stable 
transfection using non-viral tranfection.[87] Thus, differences between cells 
receiving nanog through chemical transfection compared to those receiving it 
through viral delivery might explain the lack of stable expression of nanog in 
the non-viral transfected cells. However, sustained nanog expression alone 
will unlikely induce embryonic stem cell properties in most HMSCs, but will 
increase their rate of proliferation.  
This result, and experiments that demonstrate Oct-4 functions in a 
similar manner in both HMSCs and ESCs, suggests both cell types share 
similar regulatory mechanisms. Additionally, embryonic stem cells that have 
been committed to a mesoderm lineage can be dedifferentiated by forced 
expression of nanog. We maintain that nanog acts synergistically with other 
stem cell factors to facilitate dedifferentiation. This work demonstrates the 
ability of forced expression of nanog to interact with endogenous factors to 
induce dedifferentiation and expand developmental potential of cells.  
This method may be advantageous in developing neural cells without 
the generation of tetraploid hybrids or ESCs. The ability to generate human 
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neural cells from adult stem cells allow for the advancement of replacement 
therapies for neurodegenerative diseases. Still, consideration must be given 
to how transplanted cells behave under AD-pathological conditions. We 
observed both glial and neuronal differentiation in aged wild-type mice, but it 
is uncertain whether this will translate to efficient neuronal differentiation in a 
disease model.[111, 112] Our previous work has suggested that stem cells 
will have impaired neuronal differentiation following transplantation into an AD 
model animal, which shows elevated levels of amyloid β precursor protein 
(AβPP).[113] 
A closer examination in vitro demonstrated the dose-related effects of 
AβPP in regulating glial differentiation.[114] Recently, our lab has also 
demonstrated that neuronal differentiation can be achieved by lowering levels 
of AβPP in the brain using (+)-phenserine.[115] Technology such as this 
allows both for adult cells to be used in cell replacement therapies for a 
variety of diseases and also for the ability to create disease-specific cell lines 
from patients that can be used for research and development of personalized 
drugs. Although a cure for AD may not be immediate, our results may move 
us closer toward that goal. 
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EMBRYONIC STEM CELL MARKERS DISTINGUISH CANCER STEM 
CELLS FROM NORMAL HUMAN NEURONAL STEM CELL POPULATIONS 
IN MALIGNANT GLIOMA PATIENTS 
Rationale 
The signalling pathways that regulate stem cell self-renewal and 
pluripotency are likely to have significant implications to cancer research for 
several reasons. Transplantation of embryonic stem cells form taratomas 
when transplanted but differentiated cells do not. Induced-pluripotent cells 
also have the capacity for tumorigenic transformation and forced expression 
of the gene c-Myc, a gene critical for stem cell proliferation, facilitates 
transformation of astrocytes to generate tumors with an undifferentiated 
phenotype.[116] Our previous study has demonstrated the critical role of 
nanog to expand the developmental potential of human mesenchymal stem 
cells to pluripotent cells capable of neural differentiation. In this study, we 
examine the role of embryonic stem cell genes in tumor-derived stem cells 
and posit that their differential expression in cancer stem cells make them 
attractive diagnostic and therapeutic markers. 
Chapter Summary 
Glioblastoma multiforme tumors contain a sub-population of cancer 
stem cells that contribute to malignancy and resistance to therapy. Previous 
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studies have characterized these cells based on their similarity to adult neural 
stem cells and their expression of CD133. In this study, we separated cancer 
stem cells from non-pluripotent cells comprising the bulk of the tumor based 
on their respective physical growth properties using both serum and serum-
free cell culture media. We successfully generated cancer stem cells from 
multiple tumor masses as well as from the surgical aspirate. Cancer stem 
cells were able to proliferate as non-adherent spheroids and differentiated 
along neuronal and glial lineages following culture in serum-supplemented 
media. Compared to adherent cancer cells and human fetal neural stem cells 
served as control, tumor spheroids showed increased rates of proliferation, as 
measured by BrdU incorporation, and greater resistance to differentiation, 
respectively. Further characterization of these cells was carried out using 
immunohistochemistry and real-time PCR to reveal previously undefined 
molecular markers enriched in cancer stem cells that are absent in both cells 
comprising the bulk of the tumor as well as in normal neural stem cells. These 
same markers are down-regulated following differentiation and may serve as 
important diagnostic and prognostic factors. Moreover, the presence of these 
unique markers may potentially become targets for future directed therapies. 
Introduction 
Glioblastoma Multiforme (GBM) is the most common and the most 
aggressive type of brain tumor, responsible for 18.5% of all primary CNS 
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tumors. Treatment of these tumors remains a difficult clinical challenge and 
requires a multimodal approach.[117] Despite obvious benefits, surgery alone 
or in combination with radiation therapy does not provide prolonged 
remissions, yielding median survivals of 20 and 36 weeks, respectively, for 
GBM patients.[118-121] Median survival times may be increased to up to 
nearly 15 months if over 98% of the tumor is removed[122] or if chemotherapy 
is integrated with surgery and radiation[123, 124]. Standard chemotherapy 
plus fractionated radiation therapy and surgery yields a median survival 
between 50-60 weeks.[123, 124] Unfortunately, there has been little 
improvement in survival relative to the original documented average span of 
44-52 weeks over 80 years ago[125]. The presence of a blood brain 
barrier[126, 127] and the remarkable degree of molecular heterogeneity within 
malignant glial cells[128-130] limits the therapeutic effect of chemotherapy 
and makes patient prognosis poor and recurrence rates reach close to 100%.  
The heterogeneity of these GBM tumors, and particularly the presence 
of a subpopulation of cancer stem cells (CSCs) within them, is believed to be 
critical to the tumorigenic process.[131-136] Previous studies have suggested 
that these CSC cells, identified as being positive for the surface marker 
CD133, within GBM tumors are able to give rise to new tumors following 
transplantation into nude mice.[131, 134-137] Interestingly, transplantation of 
CD133 negative cancer cells does not appear to form tumors upon 
transplantation. CD133 positive cancer stem cells have been compared to 
human neural stem cells both on growth properties and gene expression.[131, 
134, 135] However, many of these comparative studies have been carried out 
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using fetal neural stem cells rather than endogenous adult neural stem 
cells.[138] All studies that cite CD133 positivity to be an adult neural stem cell 
marker reference research on fetal or embryonic stem cell-derived neural 
stem cells.[139-142] This distinction may be important because non-fetal adult 
neural stem cells, at least in the subventricular zone, do not express CD133 
and have not been as well characterized.[143] 
Previous comparative studies of malignant glioma tumor cell 
heterogeneity fail to provide valuable information as to the similarity of cancer 
stem cells to adult neural stem cells. Many studies have cited CD133 positivity 
to be a CSC cell marker even though CD133 positivity has also been 
established as a marker for normal neural stem cells (NSCs).[137, 138, 140, 
141] Thus, the use of CD133 as a surrogate marker to identify tumor stem 
cells within a GBM may not be clinically useful as glioblastomas contain both 
differentiated cancer cells and cancer stem cells in addition to normal adult 
neural stem cells that migrate into the tumor.[144-146] Both NSCs and glial 
progenitor cells have been found throughout the healthy normal adult 
brain.[147-154] Neural stem cells travel with tumor cells migrating through the 
parenchyma of the CNS.[144] In fact, NSCs appear in the area adjacent to 
glioma implants five days after injection in mice.[146] This migratory 
phenomenon, which is also observed in brain injury[155], has been proposed 
as a means of anti-cancer gene delivery.[156, 157] If stem cells are to be a 
viable vehicle for tumor therapies, then more detailed identification is needed 
to prevent the accidental implantation of cancer stem cells. Thus, identifying a 
specific CSC marker to distinguish neoplastic stem cells from non-cancerous 
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NSCs is crucial for not only understanding the biology of tumor stem cells but 
also development of effective therapies for GBM. 
The ability of CSCs to undergo tumorigenesis, combined with their 
resistance to chemo- and radiation- therapies,[158-160] is of particular clinical 
importance given the propensity of gliomas to reemerge following surgery and 
therapy. As a result, CSC cells may represent a primary therapeutic target in 
order to achieve complete eradication of the tumor. Although CD133 positive 
CSCs have been compared to human NSCs both on growth properties and 
gene expression[131, 134, 135], definitive CSC-specific markers, which 
relates to tumor stem cell biology have not been found. To help address this 
problem, this study aimed to characterize different cell populations based on 
growth properties and to show a distinct population of cells with cancer stem 
cell properties based on specific cell marker expression patterns. 
Materials and Methods 
Cell Culture and Isolation 
Human glioblastoma tumor masses were removed from patients 
undergoing craniotomy for primary resection of newly diagnosed tumor 
identified by magnetic resonance imaging (MRI). All patients provided IRB 
approved informed consent for the study pre-operatively. Surgically removed 
tumor specimens were washed, minced, dissociated, and then placed, within 
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an hour of surgery, inside a 75cm2 flask containing re-suspension medium of 
DMEM/ F12 supplemented with 10% fetal bovine serum. Following an initial 
expansion in a monolayer, the tumor cells were switched to a defined serum-
free NSC media consisting of DMEM/F12 supplemented with 20ng/ml of basic 
fibroblast growth factor (FGF-2) and 20ng/ml of epidermal growth factor (EGF) 
to generate neural sphere formation at different time points. Specifically, cells 
were placed directly in neural stem cell media or switched at 24, 48, or 72 
hours. This culturing system generated cells with two distinct growth 
properties, adherent cells and floating sphere-forming cells. Adherent cells are 
likely differentiated tumor cells with limited proliferative potential. Floating 
neural spheres contain multipotent stem cells. Cells were analyzed using 
quantitative real-time PCR for expression of embryonic stem cell genes, stem 
cell transcription factors, and telomerase. Additional characterization included 
differentiation in media without growth factors such as FGF and EGF and 
supplemented with fetal bovine serum and immunohistochemical analysis for 
multiple protein markers. 
RNA Isolation and Quantitative Real-Time PCR 
Cell culture media was removed from cells and total RNA was 
extracted from cells using Trizol Reagent (Invitrogen) in accordance with the 
manufacturer’s protocol. Briefly, cells were spun down in a centrifuge tube at 
low speed to pellet. Media was removed and 1ml of Trizol was added to the 
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cells and incubated at room temperature for five minutes. After five minutes, 
0.2 ml of chloroform per 1ml of Trizol was added to the tubes. The tubes were 
shaken vigorously for 15 seconds and incubated at room temperature for two 
minutes. Tubes were then centrifuged at 12,000 x g for 15 minutes at 4˚C. 
Next, the aqueous phase of the samples was removed and transferred into a 
fresh tube. To precipitate the RNA, 0.5 ml of isopropyl alcohol was added to 
each tube and the tube was lightly mixed back and forth for 15 seconds. 
Samples were then incubated at room temperature for 10 minutes and 
centrifuged at 12,000 x g for 10 minutes at 4˚C. The supernatant was 
removes and the RNA pellet was washed once with 1 ml of 75% ethanol per 1 
ml of Trizol. Samples were mixed by vortexing and centrifuged at 7,500 x g for 
five minutes at 4˚C. The supernatant was carefully removed and the RNA 
pellet was air dried for approximately 10 minutes. The RNA pellet was then 
resuspended in 100 µl of microbiology grade water and tubes were incubated 
for 10 minutes at 55˚C. RNA concentration was measured using 
spectrophotometry. A 1:50 dilution was created using water and absorption 
readings were taken at 260nm (correlating to RNA concentrations) and 
280nm (the ratio of A260/A280 relating to RNA purity). The 




RNA was reverse transcribed for RT-PCR using iScript cDNA 
Synthesis Kit (Biorad) to form cDNA. The cDNA reaction took place under the 
following conditions: 25˚C for 5 minutes, 42˚C for 30 minutes, 85˚C for 5 
minutes, and held at 4˚C. 
Real-Time PCR 
Gene expression was measured by quantitative real-time PCR (qRT-
PCR) using gene specific primers. Real-Time PCR was performed using the 
MyiQ SuperCycler Real Time PCR Detector System (Biorad) using iQ 
Supermix with SYBR Green (Biorad) for detection. Each reaction tube 
contained, 12.5 µl of SYBR Green, 8 µl of microbiology grade water, 1 µl of 
forward primer, 1µl of reverse primer, and 2.5 µl of cDNA, for a total reaction 
volume of 25 µL. Primers used for real time PCR were: TERT, F 5’-
CGGAAGAGTGTCTGGAGCAA-3’, R 5’-GGATGAAGCGGAGTCTGGA-3’; 
CD133, F 5’-CAGAGTACAACGCCAAACCA-3’, R 5’-
AAATCACGATGAGGGTCAGC-3’, 
Nanog F 5’-ACAACTGGCCGAAGAATAGC-3’, R-
AGTGTTCCAGGAGTGGTTGC-3’; Sox2, F 5’-
CGGTACCCGGGGATCCCCGCATGTACAACATGATGG-3’, R 5’- 
CATAATGGCCGTCGACCACATGTGTGAGAGGGGCA-3’; Oct4 F 5’- 
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ATAGACCGGTAATGGCGGGACACCTGGC-3’, R 5’- 
CATAATGGCCGTCGACCAGTTTGAATGCATGGGAGA-3’; b-Actin, F 
5’-CTCTTCCAGCCTTCCTTCCT-3’, R 5’-AGCACTGTGTTGGCGTACAG-3’. 
The Real-Time PCR reaction consisted of Cycle 1: 1 repeat at 94˚C for 5 
minutes, Cycle 2: 45 repeats of step 1 at 94˚C for 30 seconds, step 2 at a 
gradient from 56.2-61.0˚C for 30 seconds, and step 3 at 72˚C for 45 seconds, 
Cycle 3: 1 repeat at 72˚C for 5 minutes, Cycle 4: 1 repeat at 90˚C for 1 
minute, Cycle 5: 90 repeats at 50˚C for 10 seconds with an increase in 
temperature of 0.5˚C after each cycle starting with cycle 2, and Cycle 6: 1 
repeat at 25˚C for 5 minutes. Data collection was enabled at the end of Cycle 
2 and melting curve data collection was enabled at Cycle 5. 
Immunocytotochemistry 
Immunocytotochemical staining was performed using a primary and 
fluorescent-conjugated secondary antibody protocol. Briefly, cultured cells 
were washed in phosphate buffered saline (PBS) and fixed in a 4% 
paraformaldehyde fixative solution for 20 minutes at room temperature. When 
staining for BrdU incorporation, samples were treated with 2N hydrochloric 
acid for 20 minutes then washed three times with PBS. 
Samples were then incubated at room temperature in a blocking 
solution of PBS supplemented with 5% donkey serum and 0.2% triton X for 
one hour. Sections were subsequently transferred to a blocking solution 
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containing the primary antibodies and incubated overnight at 4˚C. Primary 
antibodies for the following targets were used: Nanog, Oct4, Sox2, BrdU, 
BetaIII-tubulin, and GFAP. The following morning, sections were then washed 
and incubated in a fluorescent-conjugated secondary antibody (1:500 dilution) 
for 2 hours in the dark, at room temperature. Stained sections were then 
washed three times with PBS and mounted on a glass slide using a mounting 
medium containing DAPI to label the nuclei of the cells. 
Results 
Cells were isolated from either bulk tumor masses or a flush solution of 
surgical aspirate fluid. Tissue culture isolation of GBM patient brain tissue 
using a defined serum-free NSC media identified two general groups of cells 
that form from these tissues. The first group consisted of non-adherent 
spheroid-forming cells, while the second group consisted of cells forming a 





Figure 7: Isolation of cell populations from patient tumor samples. Cells are 
isolated from patient samples either by dissociating the bulk tumor mass using 
surgical scalpels (a) or through centrifugation of the surgical aspirate solution 
(b). Cells isolated from either approach produce populations of cells that are 
adherent or form floating spheroids. The spheroids have the properties of 




Adherent cells were more heterogenous and had lower rates of 
proliferation. Cells were treated with BrdU for 48 hours to measure 
proliferation rates and stained using antibodies specific for either CD133 or 
BrdU. Changes in morphology and the frequency of BrdU-positive cells were 
observed between the spheroid and adherent cell cultures. Moreover, CD133 
expression could be observed in both the spheroid-forming cells, even after 4 




Figure 8: Expression of CD133 and BrdU staining between adherent and 
floating stem cell cultures. Cells expanded and spheroids had higher BrdU 
staining and enriched CD133 staining within the spheroid (A). Transferring 
cells to differentiation media supplemented with 10% FBS for four days 
reduced the frequency of BrdU-positive cells, but CD133 was still expressed 
in some of the cells. (B) Although most adherent cells did not express CD133, 
some positive cells could still be observed (C). Scale bar = 63μm. 
Analysis of proliferation rates between patient tumor-derived cell lines 
revealed distinct differences in proliferation rates, as determined by BrdU-
incorporation. Cells expanding as tumor spheroids had significantly higher 
rates of proliferation compared to adherent lines or tumor spheroids placed in 
differentiation media. (Figure 9) In fact, following just four days in serum-
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supplemented media, proliferation rates in cancer stem cells were reduced by 
half (p<0.001). 
 
Figure 9: Proliferation rates measured by 48 hour BrdU-treatment Transferring 
cancer stem cells in serum-supplemented media reduced the rates of 
proliferation by 50% (p<0.001). After 48 hours, only 25% of adherent line 1 
and 13% of adherent line 3 were positive for BrdU compared to nearly 80% of 
cancer spheroids (p<0.0001). 
Immunohistochemical staining also revealed differences between the 
floating spheroid cultures, enriched for cancer stem cells, and the adherent 
cell cultures. Spheroid cultures had a low frequency of expressing markers for 
neuronal and astrocytic differentiation, as indicating with immunostaining for 
βIII-tubulin and GFAP, respectively. However, neural spheres derived from 
the primary tumors were enriched for neural stem cell markers, including Sox2 





Figure 10: Expression of stem cell and differentiation markers in tumor-
derived stem cells. Tumor-derived cells grow as non-adherent spheroids 
display low rates of GFAP and βIII-tubulin expression (A). Tumor spheroids do 
readily express stem cell markers Sox2 (B) and Nestin (C). Adherent cell 
cultures show stronger staining for neuronal differentiation markers (MAP2 
and βIII-tubulin, D) as well as astrocytic markers (S100 and GFAP, E). Cancer 
stem cells could be induced to express both neuronal (F) and astrocytic (G) 
markers following one-week differentiation in media supplemented with 
retinoic acid. Scale bar = 63μm. 
Alternatively, adherent cell cultures displayed stronger staining for both 
neuronal (βIII-tubulin and MAP2) as well as astrocytic (S100 and GFAP) 
markers. The expression of these markers could be up-regulated following 
one-week differentiation in media without EGF or FGF and supplemented with 
retinoic acid. 
The expression of neural stem cell markers by glioma-derived cancer 
stem cells has been previously reported. However, we then tested if glioma-
derived cancer stem cells express embryonic stem cell markers. Using stem 
cell gene specific primers, we compared the expression of embryonic stem 
cell markers nanog, sox2, oct4, and telomerase reverse transcriptase (TERT) 
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of cancer stem cells to the adherent non-stem cell cultures and normalized 
gene expression to beta actin (Table 1). 
Table 1 
PCR Analysis of Clones Resistant to Differentiation Relative to Normal Tumor 
Non-neurosphere Cells 
 








Note. Gene expression levels are normalized against beta-Actin gene 
expression level. 
In order to investigate the specificity of nanog as a cancer stem cell 
marker, we compared the expression of nanog from multiple experiments to 
the gene expression level of nanog from fetal-derived neural stem cells. We 
found that cancer spheroids have elevated expression of nanog relative to 




Nanog CT Values for GBM Tumor Clones  










Fetal human NS cell 27.73333 
  
Note. Fetal-derived neural stem cells have relatively lower nanog expression 




Although tumor-derived stem cells typically had higher nanog 
expression, indicated by lower Ct values, the values varied between samples. 
This reflects the heterogeneity of initial stem cell cultures and the need to 
establish clonal-derived cell lines. Moreover, it suggests that within the tumor 
mass, subpopulations of non-cancerous neural stem cells reside and can be 
isolated. 
We then carried out immunohistochemical staining to demonstrate that 
the up-regulation of gene expression translates to strong protein staining. We 
demonstrated the cancer stem cells stain positive for antibodies against 
Nanog, Oct4, SSEA4 and CD133 (Figure 11). 
 
 
Figure 11: Expression of embryonic stem cell markers in cancer spheroids. 
Sphere forming cells express embryonic stem cell markers Nanog, SSEA4, 
Oct4 and CD133.  
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The expression of embryonic stem cell markers in glioma stem cells 
provides an important differential marker that can serve to distinguish cancer 
stem cells from non-cancerous neural stem cells. 
Discussion 
We were able to demonstrate that despite the heterogeneity of tumor-
derived cell lines, distinct populations of cells can be derived based on growth 
properties. Specifically, cancer stem cells show greater proliferation and 
express a unique set of markers that are not highly enriched in the adherent 
cells comprised of cell from the bulk of the tumor. However, tumor stem cell 
lines derived had varying levels of embryonic stem cell markers. Gene 
expression analysis revealed tumor spheroids had significantly higher levels 
of embryonic stem cell genes including Nanog, Oct4, and Sox2. Although 
Sox2 is required for neural stem cell maintenance, the expression of Nanog 
and Oct4 was unexpected since previous reports suggest they are not 
expressed in human neural stem cells. Of the two cell types within the tumor 
spheroids, those resistant to differentiation had much higher levels of Nanog 
expression than those that proceeded to differentiate into neural and astroglial 
lines. This suggests that the high expressing Nanog cells may represent true 
CSCs while cells that express nanog at low concentrations, if at all, may be 




The characterization of cancer stem cells is important from a 
therapeutic and diagnostic standpoint. The ability of identify unique markers 
that are enriched in cancer stem cells will lead to novel therapeutic targets. 
Also, given the role of cancer stem cells in drug resistance and malignancy, 
these markers may serve as diagnostic markers that can provide insight into 
the best treatment options for the patient. However, the similarity between 
brain tumor cancer stem cells and normal endogenous neural stem cells 
poses a challenge. Elimination of endogenous neural stem cells may 
contribute to post-chemotherapy cognitive impairment[161, 162] and the use 
of neural stem cells and vehicles for anti-tumor therapies[144, 145, 156] 
requires quality control measures to insure transplanted cells have not been 
transformed during expansion.[163] Given that populations of neural stem 
cells and cancer stem cells grow as non-adherent tumor spheroids and 
express CD133, neither is a reliable way to differentiate tumor from non-tumor 
stem cells within a GBM tumor. Our results suggest that the tumor spheroids 
derived from GBM brain tissue do contain different stem cell populations, 
which can be distinguished by the level of embryonic stem cell gene 
expression. Nanog , a transcription factor critically involved with self-renewal 
of undifferentiated stem cells seems to be the most differentially expressed in 
these glioma stem cells. It’s levels in normal NS cells and differentiated tumor 
cells are negligible. From our results, it seems that Nanog might be a better 
CSC marker than the previously described CD133. Nanog, is thought to play 
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a key role in maintaining pluripotency. Loss of Nanog function causes 
differentiation of embryonic stem cells into other cell types and Nanog over-
expression enables stem cell propagation for multiple passages during which 
they remain pluripotent. Interestingly, p53 binds to Nanog’s promoter and 
suppresses its expression resulting in stem cell differentiation.[164, 165] 
Since Nanog is known to prevent differentiation of embryonic stem 
cells, a similar mechanism may be preventing differentiation of the CSCs. 
Future research studying Nanog’s role in regulating GBM tumor stem cell 
differentiation and ways to block Nanog’s effects on these cells may allow for 






CHARACTERIZATION OF CANCER STEM CELLS WITHIN 
GLIOBLASTOMAS AND THEIR INHIBITION WITH HISTONE 
DEACETYLASE INHIBITORS 
Rationale 
The signalling pathways that regulate stem cell self-renewal and 
pluripotency are likely to have significant implications to cancer research for 
several reasons. Transplantation of embryonic stem cells form taratomas 
when transplanted but differentiated cells do not. Induced pluripotent cells 
also have the capacity for tumorigenic transformation and forced expression 
of the gene c-Myc, a gene critical for stem cell proliferation, facilitates 
transformation of astrocytes to generate tumors with an undifferentiated 
phenotype.[116] Our previous study has demonstrated the critical role of 
nanog to expand the developmental potential of human mesenchymal stem 
cells to pluripotent cells capable of neural differentiation. In this study, we 
examine the role of embryonic stem cell genes in tumor-derived stem cells 
and posit that their differential expression in cancer stem cells make them 
attractive diagnostic and therapeutic markers. 
Cancer stem cells are highly tumorigenic and resistant to 
chemotherapy and radiation. We previously identified to role of embryonic 
stem cell genes in distinguishing these cancer stem cells, but how these 
genes are distinguished from cells comprising the bulk of the tumor has not 
been examined. We hypothesize that these stem cell genes are critical to the 
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tumorigenic process and their expression correlates with malignancy. 
Furthermore, we establish a new culturing method of isolating cancer stem 
cells from the surgical flush and identify histone deacetytase inhibitors as 
promising therapeutic options to target cancer stem cells. 
Chapter Summary 
Glioblastoma multiforme tumors are highly malignant brain tumors with 
limited effective treatment options. Within these tumors, a subpopulation of 
cancer cells with stem cell properties, have been shown to be extremely 
resistant to radiation and current chemotherapeutic agents, and have the 
ability to readily reform tumors. Therefore, the characterization of cancer stem 
cells and the development of therapeutic agents that effectively target them 
are extremely important.  
In this study, we characterize these so-called cancer stem cells based 
on gene expression using quantitative real-time PCR and 
immunohistochemical staining for stem cell markers. We successfully isolated 
cancer stem cells from both the bulk of the tumor and the surgical aspirate 
fluid, demonstrating a new isolation technique and showing heterogeneity of 
stem cells within the tumor. Moreover, we examined the effects of histone 
deacetylase inhibitors trichostatin A (TSA) and valproic acid (VPA) on the 
proliferation and gene expression profiles of cancer stem cells.  
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Cells expanded in stem cell cultures expressed both neural and 
embryonic stem cell markers Nanog, Oct4, Sox2, SSEA4, and CD133. Gene 
expression analysis showed significant enrichment of these markers in cancer 
stem cell cultures relative to cells grown in serum-supplemented media. 
Transferring cancer stem cells to serum-supplemented media reduced 
proliferation rates and greatly diminished expression of stem cell markers. 
The histone deacetylase inhibitors TSA and VPA were effective at inhibiting 
the proliferation of cells and down-regulating cancer stem cell markers.  
This study characterizes the expression of multiple embryonic stem cell 
markers in glioblastoma-derived stem cell lines. Furthermore, we demonstrate 
the effectiveness of histone deacetylase inhibitors TSA and VPA at 
significantly inhibiting cancer stem cell growth and down-regulation of stem 
cell markers. 
Introduction 
Glioblastoma multiforme (GBM) tumors are aggressive gliomas that 
demonstrate strong resistance to currently available chemotherapy options 
and frequent recurrence following treatment. After diagnosis, median survival 
times of GBM patients have been reported to be 20 weeks with surgery alone, 
or up to 36 weeks if combined with radiation therapy.[118-121, 166] Median 
survival times may be increased to nearly 15 months if either over 98% of the 
tumor is removed[122] or chemotherapy is integrated with surgery and 
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radiation treatment.[123, 124, 167] Unfortunately, this offers only a slight 
improvement relative to the average survival span of 44-52 weeks 
documented over 80 years ago.[125] 
The heterogeneity of these GBM tumors, and particularly the presence 
of a subpopulation of cancer stem cells within them, is believed to be critical 
to the tumorigenic process.[131-136] Earlier studies have demonstrated the 
existence of a subpopulation of cancer stem cells, identified as testing positive 
for the surface marker CD133, within glioblastoma tumors that are able to give 
rise to new tumors following transplantation into nude mice.[133-135, 143, 
159, 168-170] Cancer cells that are negative for CD133 did not appear to form 
tumors upon transplantation nor share stem cell characteristics observed in 
CD133+ cells.[134, 135] These CD133-positive cancer stem cells have been 
compared to human neural stem cells for both their growth properties and 
gene expression.[134, 138, 143, 159, 171]  
The ability for cancer stem cells to undergo tumorigenesis, in 
conjunction with the resistance these cells have for radiation and 
chemotherapy,[160, 172-175] is of particular clinical importance given the 
propensity of gliomas to re-emerge following treatment. This study 
characterizes different cell populations based on growth properties and shows 
the existence of a distinct subpopulation of cells with cancer stem cell 
properties. We characterize these cells based on their expression of stem cell 
markers and demonstrate the effectiveness of histone deacetylase inhibitors 
trichostatin A and valproic acid at inhibiting their growth. 
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Materials and Methods 
Cell Culture and Isolation 
Human glioblastoma cells were removed from patients undergoing 
treatment surgery who have provided informed consent for the study. 
Surgically removed tumor specimens were washed, minced, dissociated, and 
then plated inside a 75cm2 tissue culture-treated flask containing re-
suspension medium of DMEM/F12 (Invitrogen) supplemented with 10% fetal 
bovine serum (FBS, Gibco) within an hour of surgery. Following an initial 
expansion in a monolayer, the tumor cells were switched to a defined serum-
free NSC media consisting of DMEM/F12 supplemented with 2% B27 (Gibco), 
1% antibiotic/antimycotic (Gibco), 9U/ml of heparin (Sigma), 20ng/ml of basic 
fibroblast growth factor (FGF-2, R&D Systems) and 20ng/ml of epidermal 
growth factor (EGF, R&D Systems) to generate neural sphere formation at 
different time points using non-tissue culture-treated suspension flasks and 
plates. Specifically, cells were placed directly in neural stem cell media or 
switched at 24, 48, or 72 hours. This culturing system generated cells with two 
distinct growth properties, adherent cells and floating sphere-forming cells. 
Adherent cells are likely differentiated tumor cells with limited proliferative 
potential, whereas floating neural spheres contain multipotent stem cells. 
Adherent cells were expanded by enzymatic dissociation (Accumax, 
Innovative Cell Technologies); suspension cells were dissociated by quarter-
sectioning with the razor blade [176] or pelleted and dissociated with 0.5ml of 
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Accumax and gentle up-and-down pipetting for 5 minutes. Using quantitative 
real-time PCR, cells were analyzed, for expression of neural stem cell genes, 
stem cell transcription factors, tumor cell markers, and genes associated with 
neural and glial differentiation. Additional characterization included 
differentiation in serum supplemented media and antibody staining with stem 
cell and neural lineage markers. 
Isolation of Cells from Surgical Aspirate 
Surgical aspirate samples were collected during routine procedures to 
remove GBM tumors. The brain tissue was separated from the red blood cells 
by successive gradient purification (four times) through centrifugation at 300g 
using DMEM. The red blood cells formed a distinct layer that allowed for 
easier isolation of cells from the tumor. Cells were then placed in T75 
adherent and suspension culture flasks and cultured overnight in DMEM 
supplemented with 10% FBS and 1% antibiotic/antimycotic. The following 
day, cell culture media was collected and centrifuged at 200g three times 
using DMEM to collect the pellet of nucleated cells, while separating out most 
of the remaining red blood cells. The media was then changed to neural stem 
cell media to facilitate the generation of spheroids. Once spheroids were 
generated, they were cultured in suspension flasks to reduce the occurrence 
of spontaneous differentiation. The adherent cells, when nearing confluence, 
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were enzymatically-dissociated and expanded into new flasks at a 1:2 dilution 
in cell culture media. 
Culturing of Human Neural Stem Cell Lines 
Two different human neural stem cell lines were used to compare 
growth properties and to serve as a positive control for immunostaining. Fetal-
derived human neural progenitor cells (Lonza) were grown in suspension and 
expanded. Additionally, an adherent immortalized tumor cell line, ReNcell CX 
(Millipore) was grown in flasks pre-coated with laminin in non-serum stem cell 
media.[177, 178] 
Generation of Clonal-Derived Cancer Stem Cell Lines 
To generate clonal-derived cancer stem cell lines, we dissociated 
cancer spheroids and plated individual cells inside wells of a 96-well plate. 
Wells that received multiple cells were excluded from further culturing. 
Individual cells that re-grew colonies were then selected and passaged again 
in single cell cultures inside a 96-well plate to insure that spheroids were 
indeed clonally derived. This process was followed for cancer stem cells 
isolated from both the tumor mass and the surgical aspirate. 
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RNA Isolation and Quantitative Real-Time PCR 
Cell culture media was removed from cells and RNA extraction was 
performed using a commercially available TRIZOL reagent (Invitrogen). RNA 
concentrations were measured using spectrophotometry. Gene expression 
was measured by quantitative real-time PCR (qRT-PCR) using gene specific 
primers. Primers were designed using commercially available software[179] 
(Oligo 6.8, Molecular Biology Insights, Cascade, CO) and freely available 
online programs (Primer3 and Primer3 Plus).[180, 181] Given the high 
variability of “housekeeping genes,” [182-187] we tested multiple 
housekeeping genes (β-actin, GAPDH, and HPRT) and β-actin showed the 
least variation in our preliminary testing studies (data not shown). Our 
optimization results are supported by studies that suggest GAPDH and HPRT 
activity may be altered in tumors because of mutations, altered regulation or 
treatments.[182, 186-192] Primers were tested for optimal annealing 
temperature, efficient application of the target sequence, and single product 
formation. Primers that formed multiple products-such as primer dimerization-
as indicated by melt curve analysis and gel electrophoresis, were not used for 
qRT-PCR analysis. However, two different sets of nanog primers, spanning 
different exons, were used to determine if a splice variant was formed. No 




Expanded human neural stem cells or tumor-derived spheroids were 
cultured in serum-free basal media supplemented with a 1% 
antibiotic/antimycotic solution for one week to assess differentiation.[193] All-
trans retinoic acid (Sigma) at a 1μM concentration was supplemented in some 
cultures to enhance differentiation in serum-free conditions.[194-196] 
Alternatively, serum-induced differentiation was performed using serum-
supplemented (10% FBS) DMEM, each containing 1% antibiotic/antimycotic 
solution in tissue culture treated plates. 
Drug Treatments 
Histone deacetylase inhibitors (HDACi) Valproic acid (VPA) and 
trichostatin-A (TSA) stocks were prepared by dissolving the compounds in 
ethanol and then diluted to working stocks. The total ethanol concentration 
treated for cell cultures was less than 0.1% and did not affect cell growth. 
Control cells consisted of treatment with the same percentage of ethanol. 
Immunohistochemical Staining 
Immunohistochemical staining was performed using a primary and 
fluorescent-conjugated secondary antibody protocol. Briefly, cultured cells 
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were washed in phosphate buffered saline (PBS) and fixed in a 4% 
paraformaldehyde fixative solution for 20 minutes at room temperature. When 
staining for BrdU incorporation, samples were treated with 2N hydrochloric 
acid for 20 minutes then washed three times with PBS. Samples were then 
incubated at room temperature in a blocking solution of PBS supplemented 
with 5% donkey serum and 0.2% triton-X for one hour. Sections were 
subsequently transferred to a blocking solution containing the primary 
antibodies and incubated overnight at 4°C. Primary antibodies for the 
following targets were used: Nanog (1:500, Ab9220, Chemicon), Oct4 (1:500, 
MAB4401, Chemicon), Sox2 (1:500, Ab5603, Chemicon), BrdU (1:200, 
Ab6328, Abcam), βIII-tubulin (1:1000, T8660 and T2200, Sigma), and GFAP 
(1:1000, G9269 and G3893, Sigma), CD133 (1:100, Ab16518, Abcam), MAP2 
(1:500, Ab5622, Abcam), MCM2 (1:500, Ab6153, Abcam), SSEA4 (1:500, 
MAB4304, Chemicon), Nestin (1:500, MAB353, Chemicon). 
The following morning, sections were then washed and incubated in a 
fluorescent-conjugated secondary antibody (1:500 dilution) for 2 hours in the 
dark at room temperature. Stained sections were then washed three times 
with PBS and mounted on a glass slide using a mounting medium containing 




Cells were analyzed using an inverted Leica microscope with a 
mounted camera using Openlab 4.0 software (Improvision). Negative controls 
consisting of fixed cells immunostained without incubation with secondary 
antibodies were used to rule out auto-fluorescence or non-specific binding. 
Cell imaging was done using the same camera settings and exposure range 
for each sample. Images were then saved as TIFF files and combined in 
Photoshop as RBG images. Multiple samples were photographed and cells 
were counted and examined. Quantitative analysis of cell numbers was 
performed by counting of blindly-selected regions in multiple samples using 
Photoshop. 
Statistical Analysis 
Data was compiled in Microsoft Excel and GraphPad Prism software 
and statistical analysis was carried out using a minimum of three independent 
samples and graphed using the mean and standard deviation. Real-time PCR 
data was analyzed based on comparison of normalized Ct values. [50, 51, 
184, 197] Although previous studies by our lab have relied on visual 
estimations of relative gene expression[113, 114] or employed a standard t-
test for statistical analysis,[198, 199] we employed a t-test for unequal 
variance. The Student t-test holds true for data that has a normal 
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distributions,[200, 201] while the test used for these experiments does not 
assume equal variance.[202, 203] This new approach overcomes problems 
with the conventional t-test for gene expression analysis[51, 184, 204, 205] 
and does not require testing for normality,[202, 203] a required step that 
typically is not carried out. To further validate the appropriateness of this 
approach, we carried out an F-test demonstrating that our gene expression 
data does not follow a normal distribution. Cell counting was performed on 
blindly-selected regions that were photographed from at least three 
independent wells. Cell count data was analyzed for One-way ANOVA using 
Bonferroni multiple comparisons post-hoc testing.  
Results 
Isolation of Cancer Stem Cell Lines 
We attempted to generate cancer stem cell and non-stem cell lines 
from both the mass of the tumor and the surgical flush. Two distinct cell 
populations were generated from culturing cells in serum-supplemented or 
serum-free media. Cells cultured in conventional serum-supplemented media 
adhered to the flask and displayed heterogenic morphology-typically with 
branched spindle-like processes and high nuclear to cytoplasmic ratios, 
(Figure 12, A1) which is consistent with observations by multiple groups.[128, 
206-209] Contrastingly, when cultured in serum-free conditions, cells grew in 
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suspension forming spheroids (Figure 12, A2). Although serum-free 
conditions did exhibit adherent cells, they were relatively non-proliferative, and 
by the third passage, cultures consisted almost entirely of suspended cells 
resembling neural stem cell spheroids.(Figure 12) Serum-free culturing 
conditions and samples that were generated from the surgical flush had 
significantly more cellular debris compared to serum-supplemented cultures of 
cells generated from the tumor mass, simply because the floating debris is 
easily removed when changing the media of adherent cells (Figure 12, A3-4). 
Floating stem cell cultures required additional low-speed centrifugation to 





Figure 12: Morphology of cells in culture. Dissociation of tumor tissues can 
produce two distinct cell populations, adherent cells that grow in a monolayer 
in serum-supplemented culture (A1) or cells that grow in suspension in NSC 
culture conditions (A2). Cells isolated from the surgical flush are also give rise 
to monolayer (A3) and spheroid-growing cells (A4), in serum-supplemented 
and NSC culture media, respectively. More cellular debris is present with 
surgical aspirate-derived cultures. Cells grown in serum-supplemented (B1) 
and serum-free stem cell media (B2) maintain their growth patterns in 
continuous culture (5 weeks). Tumor-derived cells expanded in serum-free 
stem cells cultures resemble fetal-derived non-cancerous stem cells (B3). 




Nonetheless, by two to three weeks, floating spheres were generated 
from either cell source and were easily expanded by passaging and re-
seeding in new suspension flasks. The initial passaging of the cancer stem 
cells produced floating and adhering cells, suggesting that early passaged 
cells still contain non-stem cells or are still prone toward spontaneous 
differentiation. However, after one month of continuous culture, cell cultures 
were less heterogeneous-with retracted cytoplasmic processes compared to 
serum-cultured cells-and began to readily expand (Figure 12, B1-2). The stem 
cell cultures produced proliferating spheroids (Figure 12, B2) that resembled 
human fetal-derived neural stem cells Figure 12, B3). We also examined 
slight variations in culturing conditions to determine the optimal approach to 
generating cancer spheroids. We compared the culturing of cells after 
immediate plating in stem cell media to transference after 24, 48, and 72 
hours from serum-supplemented media. 
Surprisingly, initial culturing with only neural stem cell media produced 
very few viable neural spheres; culturing in serum media for 48 hours also 
resulted in a limited number of slow proliferating spheres; and, no spheroids 
were generated in cultures that were initially treated with serum media for 72 
hours. Culturing cells in serum media overnight prior to transferring to neural 
stem cell media yielded the most spheroids. Hence, given the time points 




Characterization of Cancer Stem Cell Lines Based on Immunohistochemistry 
We compared the expression of multiple stem cell markers among the 
adherent serum-supplemented cell cultures, the tumor spheroids, and an 
immortalized neural stem cell line, ReNcell CX. The immortalized neural 
progenitor cell line ReNcell Cx grows as an attached monolayer in plates pre-
coated with laminin. Incubation of fixed samples with only secondary 
antibodies conjugated with either FITC or TRITC revealed no detectable non-
specific binding or auto-fluorescence (Figure 13, A). The immortalized stem 
cell line shows positive immunostaining for the early neuronal and astrocytic 
markers βIII-tubulin (Figure 13, B2) and GFAP (Figure 13, B3), respectively. 
The ReNcell Cx cells were also positive for stem cell markers Nestin (Figure 
13, C2), 
CD133 (Figure 13, C3), MCM2 (Figure 13, D2), and Sox2 (Figure 13, 
D3). However, this line showed no appreciable staining for embryonic stem 




Figure 13: Expression of stem cell and lineage markers in the ReNcell Cx line. 
The immortalized neural progenitor cell line ReNcell Cx grow as an attached 
monolayer in plates pre-coated with laminin. Fixed cells were treated with 
DAPI to stain the nuclei (A-E4). They do not show positive staining when 
stained with secondary antibodies conjugated with either FITC (A2) or TRITC 
(A3). They do demonstrate expression of lineage markers βIII-tubulin (B2) and 
GFAP (B3) as well as neural stem cell markers. ReNcell Cx cells also have 
positive staining for Nestin (C2), CD133 (C3), MCM2 (D2), and Sox2 (D3). 
However, the neural stem cell line does not stain positive for the embryonic 




Adherent tumor-derived cells grown in serum-supplemented media do 
not appreciably express stem cell markers CD133 (Figure 14, A2) or Oct4 
(Figure 14, A3). However, cells do demonstrate strong expression of the 
mature neuronal marker MAP2 (Figure 14, B2) as well as the early lineage 
marker βIII-tubulin (Figure 14, B3). The cells also have strong expression of 
glial differentiation markers S100 (Figure 14, C2) and GFAP (Figure 14, C3). 
The expression of differentiation markers is consistent with their differentiated 
spindle morphology.  
 
 
Figure 14: Expression of stem cell and lineage markers in adherent tumor-
derived cells. Adherent tumor-derived cells grown in serum-supplemented 
media do not appreciably express stem cell markers CD133 (A2) or Oct4 
(A3). However, cells do demonstrate strong expression of the mature 
neuronal marker MAP2 (B2) as well as the early lineage marker βIII-tubulin 
(B3). The cells also have strong expression of glial differentiation markers 




Glioma stem cells, expanded in serum-free and growth factor-
supplemented stem cell media, did positively stain for neural and embryonic 
stem cell markers, as well as for markers of differentiation. Tumor spheroids 
express neural stem cell markers CD133 (Figure 14, A2 and 15, E2), Nestin 
(Figure 15, B2), transcription factor Sox2 (Figure 15, B3 and 15, D2) and 
proliferation marker MCM2 (Figure 15, E3). Moreover, the spheroids were 
also immunopositive for embryonic stem cell markers Nanog (Figure 15, C2), 
Oct4 (Figure 15, A3), and SSEA4 (Figure 15, C3). However, cells were 




Figure 15: Expression of stem cell markers in tumor-derived stem cells. 
Tumor-derived cells grow as non-adherent spheroids express stem cell 
markers CD133 (A2, E2), Oct4 (A3), Nestin (B2), Sox2 (B3, D2), Nanog (C2), 
SSEA4 (C3) and MCM2 (E3), but not surface marker TRA1-60 (D3). Scale 





GBM stem cells also expressed low levels of early lineage markers βIII-
tubulin (Figure 16, A3 and 16B3) and GFAP (Figure 16, A2 and 16, C3). The 
tumor-derived stem cells were also weakly positive for differentiation markers 
MAP2 (Figure 16, B2) and S100 (Figure 16, C2). Although spheroids were 
comprised of cells that were positive for both neuronal and glial markers, two 
different lineage markers were typically not expressed within the same cell. 
We also found cancer stem cells to have higher rates of proliferation relative 
to serum differentiation-induced cells and adherent non-stem cell cultures. 
Moreover, when differentiation is induced in the cancer stem cells, we 




Figure 16: Expression of lineage markers in tumor-derived stem cells. The 
cells also expressed developmental markers for neuronal (βIII-tubulin (A3) 
and MAP2 (B2)) and glial (GFAP (A2, C3), S100 (C2)) lineage differentiation. 
Scale bar = 63μm. 
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Gene Expression Analysis of Cancer Stem Cell Lines 
We next examined the relative differences in gene expression profiles 
among three different cell lines, two of which were generated from two 
different sources (tumor mass and surgical flush) from the same patient (AA1-
02 and AA1-06). We measured consistently higher expression of genes 
critical to stem cell proliferation and self-renewal in the glioma stem cells 
relative to the adherent non-stem cell cultures. Cancer spheroids derived from 
either the bulk of the tumor tissue (CSC AA1-02 and CSC AA3-01) or the 
surgical flush (CSC AA1-06) demonstrate enriched expression of stem cell 
markers and other genes compared to adherent tumor cells expanded in 
serum-supplemented cultures. Cancer stem cell line AA1-02 showed elevated 
expression of GAPDH (4.2x, p<0.01) and stem cell transcription factors nanog 
(99.1x, p<0.0001), oct4 (9.3x, p<0.01), and sox2 (1341x, p<0.00001). Cell line 
CSC AA1-06 has enhanced relative expression of stem cell markers nanog 
(20.9x, p<0.0001) and sox2 (461.2x, p<0.00001). Telomerase reverse 
transcriptase (TERT) and telomeric repeat-binding factor 1 (TERF1) were 
both significantly higher in both cancer stem cell lines (TERT: 129.0x and 





Figure 17: Cancer spheroids have enhanced stem cell gene expression 
patterns. Cancer spheroids derived from either the bulk of the tumor tissue 
(CSC AA1-02 and CSC AA3-01) or the surgical flush (CSC AA1-06) 
demonstrate enriched expression of stem cell markers and other genes 
compared to adherent tumor cells expanded in serum-supplemented cultures. 
Cancer stem cell line AA1-02 showed elevated expression of GAPDH and 
stem cell transcription factors nanog, oct4, and sox2. Cell lines CSC AA1-06 
and CSC AA3-01 show enhanced expression of stem cell markers nanog and 
sox2. Telomerase reverse transcriptase (TERT) and telomeric repeat-binding 
factor-1 (TERF1) were both significantly higher in the cancer stem cell lines. 
The stem cell genes that showed the greatest differential expression were the 
stem cell transcription factors nanog and sox2 along with tert and surface 
marker CD133. Statistical significance indicated by asterisks: *p<0.05, 
**=p<0.01, ***p<0.001, ****p<0.0001. 
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The presence of active telomerase functioning is commonly observed 
in many tumors, but is extremely low in adult neural stem cells and glioma 
cells expanded in serum-supplemented cultures. The gene Lefty, which 
regulates both embryonic stem cell expansion and early neuroectoderm 
differentiation,[210-213] was not statistically enhanced nor decreased in either 
the AA1-02 (p=0.35) nor the AA1-06 (p=0.10) line. However, the surface 
marker CD133 appears to have the greatest discrepancy in expression 
between the adherent tumor cells and tumor spheroids in CSC lines AA1-02 
(4748.6x, p<0.01) and AA1-06 (926.9x, p<0.01). 
Cancer stem cell line AA3-01 has robust over-expression of the 
embryonic stem cell transcription factors nanog (74.1x, p<0.0001), oct4 
(15.8x, p<0.001), and sox2 (106.3x, p<0.0001) relative to adherent serum-
supplemented cell cultures. This cell line also expressed higher levels of tert 
(21.1x, p<0.01), terf1 (16.2x, p=0.058), and lefty (71.2x, p<0.05). CD133, as 
expected, had significantly greater relative expression in the AA3-01 line as 
well (588.4x, p<0.01). 
The gene expression levels between the tumor mass-derived (AA1-02) 
and surgical flush-derived (AA1-06) cell lines was significantly different for 
almost all genes tested. Cell line AA1-02 showed greater relative expression 
levels of GAPDH (p<0.01), oct4 (p<0.05), sox2 (p<0.001), terf1 (p<0.05), lefty 
(p<0.05), and CD133 (p<0.05) when compared to the AA1-06 line. Although 
the relative expression of tert was enhanced in the AA1-06 line (p=0.01). 
Relative expression levels of nanog were not statistically different between the 
two lines (p=0.11). 
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Differentiation Analysis of Cancer Stem Cell Lines 
Cancer stem cells were similar to healthy neural stem cells with respect 
to morphology, a non-adherent spheroid growth pattern, and the ability to 
differentiate into neural and glial progenitors, as indicated by βIII-tubulin and 
GFAP immunostaining. However, cancer stem cells were more resistant to 
differentiation, particularly when the tumor spheroid was intact. Human fetal-
derived neural stem cells underwent differentiation when transferred to a 
serum-free and non-growth factor-supplemented basal cell culture medium 
(Figure 18, A). Cells, grown as neural spheres, attached and differentiated 
along both neuronal (βIII-tubulin, Figure 18, A1) and glial (GFAP, Figure 18, 
A2) lineages. Following one week of culturing in basal media, neural stem 
cells developed a differentiated morphology with extensive cellular processes 
(Figure 18, A). When the cancer spheroids were transferred to serum-free 
differentiation cultures, the cells attached and displayed enhanced expression 
of (βIII-tubulin, Figure 18, B1) and glial (GFAP, Figure 18, B2). However, the 
glioma stem cells were far more resistant to differentiation, particularly when 
the spheroid remained intact. (Figure 18, B) Serum-free differentiation failed 
to eliminate the expression of stem cell markers within the spheroid. After one 
week, cancer stem cells still maintained the expression of CD133 (Figure 18, 
C1) and Oct4 (Figure 18, C2). The use of retinoic acid, an enhancer of 
differentiation, was still ineffective at eliminating the expression of stem cell 




Figure 18: Differentiation of cancer spheroids. Human neural stem cells 
undergo differentiation when transferred to a serum- and growth factor-free 
basal medium. Following one week of differentiation in non-supplemented 
basal cell culture media, neural stem cell spheroids adhered to the plate and 
migrated outward, increasing the expression of βIII-tubulin (A1) and GFAP 
(A2), cancer spheroids also expressed βIII-tubulin (B1) and GFAP (B2), but 
were more resistant to differentiation. Cancer spheroids still expressed stem 
cell markers CD133 (C1) and Oct4 (C2) after one week of basal media 
differentiation. Moreover, the expression of both stem cell markers persisted 
even when cultured in basal media supplemented with retinoic acid (D1-3). 
The use of serum-supplemented media was used to induce differentiation of 
tumor spheroids (E1-4). Following four days of serum-induced differentiation, 
differentiating cells migrated away from the spheroid and had more intense 
staining for βIII-tubulin (E1), but lower staining for CD133 (E2), Sox2 (E3), and 
Nanog (E4). Serum-induced differentiation also significantly decreased 
proliferation and Sox2 expression. Scale bar = 63μm. Statistical significance 
indicated by asterisks: *p<0.05, **=p<0.01, ***p<0.001, ****p<0.0001. 
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Culturing gliomas stem cells in serum-supplemented media did 
facilitate differentiation. Following four days of serum-induced differentiation, 
cells migrated away from the spheroid and had more intense staining for βIII-
tubulin (Figure 18, E1). CD133 expression was still maintained within the 
intact spheroid, but was not readily detected in the differentiating cells outside 
the adhered spheroid (Figure 18, E2). Stem cell transcription factors Sox2 
(Figure 18, E3) and Nanog (Figure 18, E4) were detected in the spheroid, but 
only Sox2 expression was observed in the differentiating cells. 
Serum-induced differentiation has a significant impact on both the rate 
of proliferation and expression of stem cell markers (Figure 18, F). 
Proliferation, as indicated by BrdU-positive staining, showed a significantly 
decrease in the serum-induced differentiation cultures (22.8%, SD=0.05) 
compared to the non-differentiated control spheroids (77.8%, SD=11.6, 
p<0.0001). Unlike Nanog, Sox2 was still commonly expressed in the 
differentiating cells, albeit at a lower frequency compared to undifferentiated 
cells (90.3%, SD=0.03 compared to 64.9%, SD=0.09, p<0.0001). 
Rates of proliferation for the adherent and cancer stem cells in vitro 
were measured by the incorporation of BrdU over a 48-hour period. 
Immunohistochemical staining revealed a high rate of proliferation for cancer 
stem cells relative to adherent cells. Specifically, cancer stem cells showed a 
three to six times higher rate of proliferation relative to adherent cancer cells 
in vitro. Following treatment, 78 percent of cancer stem cells were positive for 
BrdU, as compared to 24.7 and 13.3 percent for two independent adherent 
cell lines (p<0.001, data not shown). 
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Effects of Histone Deacetylase Inhibitors on Cancer Stem Cell Lines 
When differentiation is induced, proliferation rates and expression of 
stem cell markers decrease. We therefore hypothesized that a drug that was 
effective at inducing differentiation would be a promising glioma adjuvant 
therapy. Although previous studies have demonstrated some anticancer 
effects of histone deacetylase inhibitors, no one has investigated their effect 
on glioma stem cells, which are highly resistant to all current 
chemotherapeutic agents marketed for glioma therapies. We tested the 
histone deacetylase inhibitors valproic acid and trichostatin A on gene 
expression and proliferation of cancer stem cells. 
Cancer stem cells proliferate rapidly in culture, yielding a high 
frequency of BrdU-stained cells (Figure 8, A2) as well as robust staining for 
CD133 (Figure 19, A4). Supplementing the stem cell media for 48 hours with 
valproic acid (1mM) or trichostatin A (1μM) decreased the number of BrdU-
positive cells (Figure 19, B-C2) and showed lower CD133 staining (Figure 8, 
B-C3). Cells also appear to have more cellular processes after exposure to 
either VPA (Figure 19, B) or TSA (Figure 19, C), indicating induction of 




Figure 19: Histone deacetylase inhibitors alter glioma stem cell morphology. 
Cancer stem cells proliferate rapidly in culture, yielding a high frequency of 
BrdU-stained cells (A2) as well as robust staining for CD133 (A4). 
Supplementing the stem cell media with valproic acid (VPA, 1mM) or 
trichostatin A (TSA, 1μM) decreased the number of BrdU-positive cells (BC2) 
and showed lower CD133 staining (B-C3). Cells also appear to have more 
cellular processes after exposure to either VPA (B) or TSA (C), indicating 




Treatment with 1mM valproic acid significantly reduced the rate of 
glioma stem cell proliferation, decreasing the frequency of BrdU-positive cells 
from 78% to 60% (Figure 20) (p<0.01). Exposure to trichostatin A had an even 
more profound reduction in proliferation, reducing the frequency of cells that 
underwent proliferation to 34% (p<0.001). 
 
 
Figure 20: Valproic acid and trichostatin A reduce glioma stem cell 
proliferation. Treatment with 1mM valproic acid significantly reduced the rate 
of glioma stem cell proliferation, decreasing the frequency of BrdU-positive 
cells from 78% to 60% (p<0.01). Exposure to trichostatin A had an even more 
profound reduction in proliferation, reducing the frequency of cells that 
underwent proliferation to 34% (p<0.001). 
Treatment with histone deacetylase inhibitors valproic acid and 
trichostatin A significantly lowered the expression of stem cell genes while 
increasing the expression of lineage differentiation markers. Expression of 
CD133 and nanog dramatically reduced when cultured with either VPA (88.0 
and 99.8% reduction in CD133 and nanog, p<0.05 and p<0.0001, 
respectively) or TSA (86.7% and 99.2%, p<0.05 and p<0.0001). Valproic acid 
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inhibited oct4 expression (53.7% reduction, p<0.01), while TSA had a 71% 
reduction in sox2 levels (p<0.01). The embryonic stem cell marker zfp342 was 
abated by both drugs (76.2 and 70.1% reduction, p<0.01 and p<0.01). 
Telomerase reverse transcriptase expression was diminished by both VPA 
(54.6% reduction, p<0.01) and TSA (80.8% reduction, p<0.05), whereas 
levels of terf1 were not significantly altered. Interestingly, there were no 
changes in the levels of the apoptosis inhibitor Bcl-xL or its repressor Bcl-xs. 
Culturing with the drugs did up-regulate differentiation markers βIII-tubulin 
(VPA: 2.1x increase, p<0.01) and GFAP (VPA: 3.1x increase, p<0.01, TSA: 
4.6x increase, p<0.01) (Figure 21). 
 
 
Figure 21: Valproic acid and trichostatin A negatively regulate the expression 
of stem cell genes. Treatment with histone deacetylase inhibitors valproic acid 
and trichostatin A significantly lowered the expression of stem cell genes 
while increasing the expression of lineage differentiation markers. Expression 
of CD133 and nanog dramatically reduced when cultured with either VPA or 
TSA. Valproic acid inhibited oct4 expression, while TSA reduced levels of 
sox2. The embryonic stem cell marker zfp342 was abated by both drugs. 
TERT was also diminished by both HDACi, whereas levels of terf1 were not 
significantly altered. Interestingly, there were no changes in the levels of the 
apoptosis inhibitor Bcl-xL or its repressor Bcl-xs. Culturing with the drugs did 




Here we report the ability to generate cancer spheroids from the 
surgical aspirate of glioblastoma surgeries. The derivation of multiple cell 
populations from the surgical aspirate offers unique advantages compared to 
relying on merely the tumor mass. The cells in the aspirate are more 
disaggregated and avoid the need for extended mechanical dissociation 
and/or enzymatic digestion. Additionally, viable recovery of multiple cell types 
may allow for the recovery of healthy neural stem cells that migrate to the 
tumor. Following rigorous quality control measures, these healthy cells may 
be transplanted back to the patient to help facilitate recovery, or, given their 
ability to migrate to tumors, used to deliver anti-tumor compounds. 
Potential questions arise regarding differences between cells derived 
from the tumor mass and those from the surgical aspirate-the later 
presumably being partially comprised of healthy brain matter. Our studies 
indicate, at least with respect to the cancer-derived spheroids, that both 
populations resist differentiation and show rapid rates of proliferation. 
Following expansion, we believe that there is a selective advantage with the 
tumor cells relative to the healthy brain cells that are either non-proliferative or 
display slow cell cycle kinetics. When comparing the two populations, their 
gene expression profile is surprisingly similar when examining a host of stem 
cell genes. These stem cells genes have been reportedly expressed in 
malignant tumors at varying levels, but the similar profile suggests that the 
spheroids derived from the mass and flush are similar in nature. 
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Culturing conditions have a large impact on the generation of spheroids 
in culture. Specifically, culturing cells for 24 hours in serum media produced 
dramatically more spheroids than culturing directly in neural stem cell media 
or continuing in culture beyond 24 hours. This skewed distribution suggests 
that components within the serum may irreversibly change the fate of the 
stem cells. 
The effects of serum on the glioma cell cultures likely skew the cultures 
in two distinct ways. First, serum induces differentiation of both non-
cancerous neural stem cells and glioma-derived stem cells. Therefore, serum 
culture would quickly eliminate stem cell sub-populations through 
differentiation. Second, serum-supplemented culture is a radically different 
environment compared to the in vivo tumor environment. This change in 
environment causes dramatic changes in gene expression within three 
passages.[214] In fact, genomic profiling reveals that after only two weeks in 
culture, seven out of eight glioma samples saw the genomic pattern in 
adherent serum-based culture diverge from the parent tumor, whereas 
spheroid suspension cultures preserved the genomic profile of the original 
tumor.[215] 
Gene expression analysis revealed tumor spheroids had significantly 
higher levels of embryonic stem cell genes including Nanog, Oct4, and Sox2. 
Although Sox2 is required for neural stem cell maintenance, the expression of 
Nanog and Oct4 was unexpected since previous reports suggest they are not 
expressed in neural stem cells. Our own analysis shows that both are not 
appreciably expressed even in immortalized neural progenitor cell lines. 
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The higher expression levels of TERT in the cancer stem cell cultures 
demonstrates the importance of telomerase activity in cancer stem cells and 
supports the use of it as a clinical marker. However, the elevated expression 
of TERF1 challenges reports that show TERF1 to be inversely correlated to 
malignancy. These results, although unexpected, may be explained by three 
potential hypotheses. First, cancer stem cells are a subpopulation within the 
tumors, and the lower expression of TERF1 may be the result of a larger 
percentage of non-cancerous cells comprising the glioma mass. Second, the 
elevated levels of TERF1 within the cancer stem cells still may be lower than 
the overall expression in lower grade tumors. Finally, the cancer stem cells 
may be unresponsive to TERF1, thereby not being affected by higher relative 
expression. The fact that TERF1 has almost no detection in non-tumor 
tissues, [216] combined with our data showing no difference in expression 
following HDACi treatment, suggests a combination of the second and third 
theories.  
Our study demonstrates a clear inhibitory affect of HDACi on glioma 
stem cells. These data challenges other reports demonstrating an increase in 
CD133 in gliomas cell lines following treatment with valproic acid and 5-aza-
2’deoxycytidine.[217] The authors use commonly available glioma cell lines 
and convincingly demonstrate that treatment with 5-aza-C and VPA results in 
promoter hypo-methylation and expression of CD133. However, upon closer 
inspection of their data, their treatment had the opposite effect in their U87MG 
cell lines. The U87MG line is unique from the other lines given the higher 
basal expression of CD133. Moreover, the U87MG line is highly tumorigenic, 
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readily forming tumors upon transplantation, whereas most glioma cell lines, 
including the T98G line, are not.[218] The differences observed with the 
U87MG line are particularly significant since it is the most well-characterized 
gliomas line containing a sub-population of cancer stem cells.[185, 219-223] 
Alternatively, the effects of HDACi may be dependent on p53 status, 
but that study demonstrated that phenylbutyrate sensitizes glioma cell lines 
with mutated p53 (U251 and SKMG-3) and did not affect wild-type cells (U87 
and D54).[224] 
Immunohistochemical staining showed positive staining for CD133 in 
adherent and cancer spheroids. The expression of CD133 in both populations 
of cells raises questions regarding its specificity for cancer stem cells. Tumor 
spheroids and adherent cancer cells show CD133 positive and negative cell 
populations, although the spheroids are largely positive. Earlier findings 
suggest that populations of cancer stem cells are CD133 negative, as we 
have observed. However, the expression of CD133 on the adherent cells, 
which are far less tumorigenic, suggests that CD133 alone is not a sufficient 
cancer stem cell marker and/or there is a morphologically distinct population 
of cancer stem cells. The notable difference between CD133 expression 
among adherent cell populations may be reflective of differences in the tumor 




These markers, given their enrichment in cancer stem cells, may serve 
as powerful diagnostic and prognostic markers for malignant tumors. The 
systematic evaluation of these cancer stem cells is important in targeting them 
for treatment by compounds that selectively induce cell death or make them 
sensitive to chemotherapy. We demonstrate histone deacetylase inhibitors 
are effective at inhibiting proliferation and reducing the expression of 
malignant markers in GBM-derived stem cells, making them a promising 
therapeutic option.   
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